Key Takeaways SLB reported Q2 2026 EPS of 55 cents, beating estimates on revenue growth in Digital and Production Systems.SLB's Digital revenues increased 18% y/y, while annualized recurring revenues rose 15% to $1.04 billion.SLB expects Data Center Solutions to exceed a $1 billion annualized revenue run rate by year-end. SLB N.V. (SLB - Free Report) reported second-quarter 2026 adjusted earnings per share (EPS) of 55 cents, which beat the Zacks Consensus Estimate of 51 cents by 7.84%. The bottom line declined 26% from 74 cents in the year-ago quarter.
The oilfield services giant recorded quarterly revenues of $8.97 billion, which topped the Zacks Consensus Estimate of $8.71 billion by around 3%. The top line increased 5% year over year from $8.55 billion.
The better-than-expected quarterly results were primarily driven by growth in Digital and Production Systems, along with broad-based gains outside the Middle East. As of June 30, 2026, digital annualized recurring revenues reached $1.04 billion, up 15% from the prior-year figure of $904 million.
SLB's Geographic Mix Supports GrowthInternational revenues were $6.67 billion, down 3% year over year. North America revenues increased 36% year over year to $2.24 billion. ChampionX contributed $870 million in quarterly revenues.
Latin America revenues increased 9% year over year to $1.71 billion, aided by higher OneSubsea revenues, digital exploration sales and offshore drilling in Brazil. Europe and Africa revenues declined 3% to $2.39 billion, while Middle East and Asia revenues fell 16% to $2.57 billion.
Digital Momentum Lifts SLB ResultsDigital revenues increased 18% year over year to $697 million from $591 million in the year-ago quarter. Growth was driven by stronger Digital Exploration sales in Brazil and Indonesia, and wider adoption of Digital Operations. Lower sales of permanent licenses caused a minor dip in Platforms and Applications, which was slightly offset by higher SaaS-based revenues.
The segment's pretax operating income increased 27% year over year to $194 million. Pretax operating margin expanded 187 basis points to 27.8%, supported by exploration data license sales and improved profitability in Digital Operations and Platforms and Applications.
SLB Core Segments Face Uneven TrendsReservoir Performance revenues declined 8% year over year to $1.56 billion from $1.69 billion recorded in the year-ago quarter, as lower evaluation, stimulation and intervention activity in the Middle East offset stronger activity in Europe and Africa, and Asia. Pretax operating income fell 26% to $232 million.
Well Construction revenues decreased 7% year over year to $2.74 billion from $2.96 billion recorded a year ago. Pretax operating income dropped 24% to $417 million. Middle East disruptions remained the main pressure, partly offset by increased offshore drilling in Latin America and improved U.S. land activity.
Production Systems Strengthens SLB's QuarterProduction Systems revenues increased 29% year over year to $3.77 billion from $2.93 billion. The ChampionX production chemicals and artificial lift businesses contributed $865 million. Excluding the acquisition, segment revenues declined 1% year over year.
Pretax operating income increased 19% to $586 million, while margin contracted 120 basis points year over year to 15.5%. Margin shrank due to weak results in surface production systems and completions, but profit from ChampionX’s production chemical and lift businesses partially offset the decline.
SLB Cash Flow & Capital Returns ImproveCash flow from operations was $1.36 billion in the second quarter, while free cash flow totaled $716 million. SLB ended June with $4.07 billion in cash and short-term investments and $11.14 billion in long-term debt.
The company repurchased 12 million shares for $648 million during the quarter. Its board approved a quarterly cash dividend of 29.5 cents per share, payable Oct. 8, 2026, to shareholders of record as of Sept. 2.
Data Center Growth & SLB's OutlookData Center Solutions revenues reached $186 million, increasing 80% year over year. First-half revenues increased 63% to $327 million. Management expects the business to exceed a $1 billion annualized revenue run rate by year-end. SLB expects Data Center Solutions to surpass a $2 billion annualized revenue run rate exiting 2027.
The company maintained its 2026 capital investment guidance at approximately $2.5 billion, covering capital expenditures, exploration data costs and Asset Performance Solutions investments.
SLB’s Zacks Rank & Key PicksSLB currently carries a Zacks Rank #4 (Sell).
Some better-ranked stocks from the energy sector that have yet to release their second-quarter 2026 earnings are Cheniere Energy, Inc. (LNG - Free Report) , TechnipFMC plc (FTI - Free Report) and NOV Inc. (NOV - Free Report) . LNG sports a Zacks Rank #1 (Strong Buy), while NOV and FTI carry a Zacks Rank #2 (Buy) each, at present. You can see the complete list of today’s Zacks Rank #1 stocks here.
Houston, TX-based Cheniere Energy is primarily engaged in the liquefied natural gas business. LNG owns and operates major liquefaction and export facilities on the U.S. Gulf Coast, including the Sabine Pass and Corpus Christi terminals.The company is involved in liquefied natural gas and natural gas marketing. With growing demand for cleaner energy, LNG is well-positioned to meet this need through its liquefaction and export facilities. Cheniere Energy is scheduled to release second-quarter 2026 earnings on Aug. 6, 2026.
TechnipFMC provides advanced technologies, products and services for subsea, surface and onshore/offshore energy projects. As global oil and gas demand is expected to grow, the company is leveraging its iEPCI Subsea, iComplete Integrated System, Subsea Studio and record backlog of more than $16.5 billion as of March-end 2026 to drive future growth. FTI is scheduled to release second-quarter 2026 earnings on July 30, 2026.
Houston, TX-based NOV is a global leader in the design, manufacture and sale of advanced equipment and components used in the oil and gas drilling, production, and renewable energy sectors. By leveraging its extensive proprietary technology portfolio, the company is well-positioned to reduce marginal costs and capitalize on the growing demand for oil and gas in the coming years. NOV is scheduled to release second-quarter 2026 earnings on July 28, 2026.
AI’s Power Crunch Fuels a Pivot for These 2 Oilfield StocksSLB NYSE: SLB reported second-quarter revenue of $9 billion, up 3% sequentially, as growth in Latin America, Europe and Africa, U.S. land and Asia more than offset disruptions in the Middle East. Adjusted earnings per share were $0.55, up $0.03 from the prior quarter but down $0.19 from a year earlier, according to Chief Financial Officer Stephane Biguet.
The company said Middle East revenue declined 13% sequentially to $1.66 billion amid conflict-related operational disruptions. SLB took temporary cost actions to limit the earnings impact, and Biguet said the resulting effect on earnings per share was slightly below the low end of the company’s previously indicated $0.06 to $0.08 range.
Get SLB alerts:
MarketBeat Week in Review – 05/04 - 05/08Despite those disruptions, SLB said its pre-tax segment operating margin increased 49 basis points sequentially and adjusted EBITDA margin rose 83 basis points.
Production Systems and Digital Lead Growth Chief Executive Officer Olivier Le Peuch said growth outside the Middle East was broad-based, supported by higher offshore activity in Brazil, Guyana, Mexico, Scandinavia, Nigeria, China, Indonesia, India and Australia. U.S. land activity also improved, with higher demand for production chemicals, artificial lift and valves.
SLB’s Tough Quarter Masks a Powerful Long-Term ShiftProduction Systems was the company’s largest division in the quarter, with revenue rising 7% sequentially to $3.8 billion. The increase was driven by OneSubsea, artificial lift, valves, surface production systems and completions. Pre-tax operating margin improved 138 basis points to 15.5%, aided by better profitability in OneSubsea and artificial lift, as well as contributions from ChampionX’s Production Chemicals and Artificial Lift businesses.
Le Peuch said Production Systems adjusted EBITDA margins returned to above 20%. He added that ChampionX delivered sequential margin expansion for a third consecutive quarter despite inflation in chemicals.
Digital revenue increased 9% sequentially to $697 million, while pre-tax operating margin rose 683 basis points to 27.8%. Digital adjusted EBITDA margin reached 34.7%, up 860 basis points sequentially, driven by exploration data licenses and transfer fees in Brazil and Indonesia, along with improved profitability in digital operations, platforms and applications. SLB said digital annual recurring revenue increased 15% year over year.
Reservoir Performance revenue declined 2% sequentially to $1.6 billion, and Well Construction revenue also fell 2% to $2.7 billion, primarily because of Middle East disruptions. Well Construction margin was essentially flat as lower profitability in the Middle East was offset by improved profitability in North America and Latin America.
Middle East Recovery Remains Uneven Management said activity resumed in several Middle Eastern countries during the quarter, though operations in Iraq remained constrained by security concerns. Le Peuch said recovery will vary by country, customer and operating environment, and a return to full activity will take time.
During the question-and-answer session, Le Peuch said customer engagement had increased as operators plan to restore shut-in wells, expand capacity and deploy production-recovery solutions. He said activity had been restored and was strengthening in the United Arab Emirates, Qatar and, to some extent, Saudi Arabia, while Iraq remained more constrained.
SLB expects initial recovery work to include well intervention, production chemicals, coiled tubing and other ChampionX-related production and recovery offerings. Management also said the disruption could accelerate interest in digital tools to optimize existing wells and operations.
For the third quarter, SLB’s base case assumes a gradual Middle East recovery and calls for global sequential revenue growth of 3% to 4%, with approximately 75 basis points of adjusted EBITDA margin expansion. Core-division revenue is expected to rise in the low- to mid-single digits, while Digital revenue is projected to increase in the low single digits.
The company also outlined a downside scenario in which renewed escalation prevents remobilization efforts and leaves Middle East revenue flat sequentially. In that case, third-quarter revenue would be about $150 million below its base case and adjusted EBITDA would face an approximately $75 million headwind, primarily in Well Construction and Reservoir Performance.
Deepwater Activity and Fourth-Quarter Outlook Le Peuch said the market is beginning to show characteristics of an upcycle, citing the need to replenish inventories and strategic reserves, diversify supply, develop domestic resources and rebuild spare capacity. He said third-party reports indicate final investment decisions for long-cycle projects could increase about 30% year over year in 2026.
SLB expects stronger exploration spending and deepwater capital investment during the second half of 2026, led by Africa, with a more meaningful impact in 2027 across Latin America, the Mediterranean and Asia. Management also highlighted continued activity in Brazil, Guyana, Suriname, the North Sea and the Gulf of America.
The company reiterated its ambition for OneSubsea bookings to reach $9 billion over two years. Le Peuch said SLB is expanding its subsea portfolio, including trees, manifolds, umbilicals, processing and boosting solutions, while pursuing life-of-field service capabilities and alliances with customers and partners.
For the fourth quarter, SLB expects Middle East revenue of $2.1 billion to $2.2 billion, or roughly 95% of the level achieved in the fourth quarter of 2025. Assuming that recovery, continued deepwater momentum and typical year-end Digital product sales, the company expects fourth-quarter revenue to exceed $10 billion, representing about 5% year-over-year growth. Adjusted EBITDA margin is expected to be about 24%.
Data Center Business Expands SLB said its data center solutions revenue grew 33% sequentially and 80% year over year. The business added hyperscaler customers and expanded from equipment manufacturing into data center design, engineering and system integration.
Le Peuch said SLB uses off-site fabrication to produce modular equipment for server infrastructure and cooling systems, aiming to provide customers with shorter delivery times and scalable deployment. The company said its backlog is already sufficient to support an annualized revenue run rate exceeding $2 billion by the end of 2027.
Biguet said the data center business is not currently accretive to SLB’s overall margins, but it is accretive to revenue and earnings growth and has strong free-cash-flow characteristics because of its capital-light business model and contract terms.
SLB generated $1.4 billion in cash flow from operations and $716 million in free cash flow during the quarter. It ended the period with net debt of $8.7 billion, repurchased $648 million of stock, and maintained its full-year target to return more than $4 billion to shareholders through dividends and buybacks.
About SLB (NYSE:SLB)SLB NYSE: SLB, historically known as Schlumberger, is a leading global provider of technology, integrated project management and information solutions for the energy industry. Founded by Conrad and Marcel Schlumberger in 1926, the company develops and supplies products and services used across the exploration, drilling, completion and production phases of oil and gas development. Its offerings are intended to help operators characterize reservoirs, drill and complete wells, optimize production and manage field operations throughout the asset lifecycle.
SLB's product and service portfolio spans reservoir characterization and well testing, wireline and logging services, directional drilling and drilling tools, well construction and completion technologies, production systems, and subsea equipment.
This instant news alert was generated by narrative science technology and financial data from MarketBeat in order to provide readers with the fastest reporting and unbiased coverage. Please send any questions or comments about this story to [email protected].
Should You Invest $1,000 in SLB Right Now?Before you consider SLB, you'll want to hear this.
MarketBeat keeps track of Wall Street's top-rated and best performing research analysts and the stocks they recommend to their clients on a daily basis. MarketBeat has identified the five stocks that top analysts are quietly whispering to their clients to buy now before the broader market catches on... and SLB wasn't on the list.
While SLB currently has a Moderate Buy rating among analysts, top-rated analysts believe these five stocks are better buys.
View The Five Stocks Here
Enter your email address and we’ll send you MarketBeat’s list of ten stocks set to soar in Summer 2026, despite the threat of tariffs and what's happening in Iran. These ten stocks are incredibly resilient and are likely to thrive in any economic environment.
Key Takeaways ECL's Q2 revenues are estimated to rise 9.3%, while earnings are projected to improve 10.1%.High-Tech, Life Sciences, Digital and Pest Elimination are expected to remain key growth drivers.Higher commodity, logistics and energy costs may pressure margins before pricing fully catches up. Ecolab (ECL - Free Report) is scheduled to release second-quarter 2026 results on July 28, before the opening bell. In the last reported quarter, the company delivered earnings in line with the estimates. ECL’s earnings beat estimates in two of the trailing four quarters, missed once and met once, delivering an average surprise of 0.23%.
Q2 Estimates
Currently, the Zacks Consensus Estimate for revenues is pegged at $4.4 billion, indicating growth of 9.3% year over year. The consensus mark for earnings is pinned at $2.08 per share, indicating an improvement of 10.1%.
Factors to Note Before ECL ReportsEcolab is expected to have delivered another quarter of organic growth, supported by continued value pricing, resilient demand across most end markets and sustained momentum in its higher-growth businesses. Global High-Tech, Digital, Life Sciences and Pest Elimination are likely to have remained the key growth drivers, benefiting from ongoing AI infrastructure investments, accelerating digital adoption, robust biopharmaceutical demand and continued customer adoption of connected pest management solutions. However, elevated commodity, logistics and energy costs, along with the temporary lag in pricing recovery, are expected to have pressured second-quarter margins and earnings growth.
Within the Global Industrial segment, Global High-Tech is expected to have maintained strong double-digit growth, supported by continued investments in semiconductor fabrication facilities, AI-driven data center expansion and rising demand for advanced water management solutions. Life Sciences is also likely to have delivered another quarter of double-digit growth, aided by robust demand for bioprocessing solutions, expanding biologics production and favorable capacity utilization. Meanwhile, Food & Beverage is expected to have outperformed its underlying markets, supported by innovation and the company's One Ecolab strategy. Paper and Heavy Water businesses, however, likely remained relatively soft despite signs of stabilization and incremental gains from new business wins.
The Global Institutional & Specialty segment is expected to have delivered steady growth, supported by continued value pricing, market share gains and demand from restaurant, lodging and quick-service restaurant customers. Specialty is likely to have remained a standout performer, benefiting from customer demand for productivity-enhancing and resource-efficient solutions that lower labor, water and energy costs. The company's One Ecolab initiative, including cross-selling efforts among its largest customers, is also expected to have supported revenue growth during the quarter.
Per management, Ecolab expects second-quarter 2026 to serve as a transition period as elevated commodity, energy and logistics costs temporarily pressure earnings before pricing actions and energy surcharges are fully realized. While the company did not provide specific revenue or earnings per share (EPS) guidance for the quarter, it expects underlying performance to remain within its long-term adjusted EPS growth target of 12-15%, with higher commodity costs expected to reduce second-quarter EPS growth by a few percentage points. Pricing is anticipated to have accelerated through the quarter, allowing Ecolab to fully offset the dollar impact of higher input costs by the end of the second quarter.
Meanwhile, favorable business mix, continued strength in higher-margin growth engines such as Global High-Tech and Life Sciences, SG&A productivity initiatives and digital efficiencies are expected to have partially cushioned inflationary pressures during the quarter. Investors will closely monitor management's commentary on pricing realization, margin recovery, demand trends across key end markets and the initial contribution and integration of the recently acquired CoolIT business, particularly as Ecolab enters the second half of 2026 with its full-year adjusted EPS growth outlook of 12-15% intact, excluding the temporary acquisition-related impact.
Earnings Beat UnlikelyOur proven model does not predict an earnings beat for ECL this earnings season. The combination of a positive Earnings ESPand a Zacks Rank #1 (Strong Buy), 2 (Buy) or 3 (Hold) increases the chances of an earnings beat, which is not the case here.
Earnings ESP: Earnings ESP, which represents the difference between the Most Accurate Estimate and the Zacks Consensus Estimate, is +0.20%. You can uncover the best stocks to buy or sell before they are reported with our Earnings ESP Filter.
Zacks Rank: The company carries a Zacks Rank #4 (Sell) at present.
Stocks Worth a LookHere are some other medical product stocks worth considering, as these have the right combination of elements to post an earnings beat this reporting cycle.
Henry Schein (HSIC - Free Report) has an Earnings ESP of +0.41% and a Zacks Rank #2 at present. You can see the complete list of today’s Zacks #1 Rank stocks here.
HSIC’s earnings surpassed estimates in three of the trailing four quarters and missed once, with the average surprise being 3.74%. The Zacks Consensus Estimate for HSIC’s second-quarter EPS indicates an improvement of 10.9% from the year-ago reported figure.
Alcon (ALC - Free Report) has an Earnings ESP of +3.13% and a Zacks Rank of 3 at present. The company is set to release second-quarter 2026 results on Aug. 10.
ALC’s earnings surpassed estimates in three of the trailing four quarters and missed once, with the average surprise being 3.66%. The Zacks Consensus Estimate for ALC’s second-quarter EPS implies an improvement of 1.3% from the year-ago reported figure.
Cardinal Health (CAH - Free Report) has an Earnings ESP of +1.24% and a Zacks Rank of 2 at present. The company is slated to release fourth-quarter fiscal 2026 results on Aug. 11.
CAH’s earnings surpassed estimates in each of the trailing four quarters, the average surprise being 10.27%. The Zacks Consensus Estimate for CAH’s fourth-quarter EPS indicates a gain of 16.4% from the year-ago reported figure.
NEW YORK, July 24, 2026 (GLOBE NEWSWIRE) -- The Gross Law Firm issues the following notice to shareholders of ZoomInfo Technologies Inc. (NASDAQ: GTM).
Paul Singer’s Elliott Investment Management just handed retail investors a cheat sheet. The latest 13F filing, disclosing holdings as of March 31, 2026, reveals five US-listed long positions that stretch from precious metals royalties to AI infrastructure. One of them has already returned 90.1% since the filing date. The other four are still setting up. Here is where the money is moving, and whether you can still get in.
1. Triple Flag Precious Metals (TFPM): The Surprise Pick A gold streamer is rare territory for Elliott, and that is exactly why Triple Flag Precious Metals (NYSE:TFPM) belongs at the top of the list. The $6.43B royalty and streaming name is a pure play on gold at a time when the metal is repricing every commodity cycle assumption, and the stock has drifted lower even as its fundamentals have exploded.
Q1 FY26 landed with adjusted EPS of $0.45 against a $0.42 estimate, revenue of $146.99M up 78.7% year over year, and a realized gold price of $4,873 per ounce versus $2,860 a year earlier. Gross margin expanded to 72% and net income jumped 156.87% on record 30,166 GEOs sold. Our model pegs base case fair value at $35.95, a 31.73% upside from the $27.29 current price, with 73% of analysts bullish and zero bears. Screens as a Buy.
Error: Invalid chart data JSON
The stock has fallen 21.6% since the 13F reference date of March 31, 2026. Elliott’s paper P&L on TFPM is underwater at current prices. Next up is a name where Singer’s paper is already very much in the black.
2. Suncor Energy (SU): The Cash Machine Masquerading as a Miss Suncor Energy (NYSE:SU | SU Price Prediction) is the integrated oil sands and refining giant that headline-scanning traders punished on a Q1 EPS miss and then quietly bought back. This is Elliott territory: a business printing cash while traders debate the wrong number.
Q1 FY26 EPS came in at $1.36 versus a $1.93 estimate, but adjusted operating earnings actually rose to $1.62B from $1.15B, and free cash flow surged 188.13% year over year to $2.05B. Management responded by lifting the monthly buyback pace from $275M to $350M, targeting nearly $4 billion in 2026 repurchases, over 30% higher than 2025. Our model reads Suncor as near fair value with 0.25% upside to a $62.02 base case. Screens as a Hold, but one that is paying shareholders to wait.
Elliott’s paper is up modestly here, with SU still down 7.61% from the March 31 filing reference even after a 60.35% one-year run. If Suncor is the boring compounder, the next name is the opposite: the one where the market has already sprinted past the activist thesis.
3. Phillips 66 (PSX): The Activist Heavyweight Running Hot This is the obvious one. Phillips 66 (NYSE:PSX) is the flagship of Elliott’s current activist book, with the fund publicly pushing for a midstream separation. Refining margins are back, buybacks are flowing, and the crowd has piled in.
Q1 FY26 delivered adjusted EPS of $0.49 against a -$0.39 estimate, revenue of $33.00B up 8.2%, and refining margins of $10.11 per barrel versus $6.81 a year earlier. Buybacks hit $269M in Q1 and the annualized dividend was raised 7% to $1.265. The problem: the stock has ripped to $206.33, above the $198.44 analyst target, and our base case models a 20.27% drawdown to $164.52 over the next year. All three of our scenarios, bull, base, and bear, produce negative to flat one-year returns. Screens as a Sell into strength based on our modeled downside.
Act now: the analyst who called NVIDIA in 2010 just named his top 10 AI stocks — and Phillips 66 didn't make the cut. Grab the names FREE today.
Elliott is sitting on gains of 11.29% since March 31 and 68.37% over one year. The activist thesis worked. The trade has aged. And the next name on Singer’s list has an even longer activist history behind it.
4. Southwest Airlines (LUV): The Turnaround Elliott Built Southwest Airlines (NYSE:LUV) is the case study for what Elliott activism produces. The fund reshaped the board, drove the commercial overhaul, and the Q1 numbers now show the model working, if fuel cooperates.
Q1 FY26 posted EPS of $0.45 versus $0.4739 consensus, revenue of $7.249B up 12.8%, and net income of $227M against a $149M loss a year earlier. RASM grew 11.2% YoY, roughly 60% of customers bought up to assigned or extra legroom seats, and Rapid Rewards enrollments jumped 37%. CEO Bob Jordan called it a “turning point for Southwest,” even as Q2 fuel guidance leapt to $4.10 to $4.15 per gallon. Our model puts fair value at $49.99, only 4.48% above the $47.85 current price. Screens as a Hold. The easy money on the activist trade has already been made.
Error: Invalid chart data JSON
LUV has already surged 32.1% since the March 31 filing reference. But the biggest Elliott win, and the punchline of this list, is not in the sky.
5. Hewlett Packard Enterprise (HPE): The Payoff Elliott’s Chris Hsu now sits on the board of Hewlett Packard Enterprise (NYSE:HPE), confirming the activist stake and giving Singer a seat at the table for what has already become the trade of 2026. The Juniper Networks integration turned a legacy enterprise IT name into an AI infrastructure operator.
Q2 FY26 (reported June 1, 2026) obliterated guidance. Non-GAAP EPS came in at $0.79 against a $0.51 to $0.55 range, revenue was $10.68 billion up 40%, and Networking revenue exploded 148.2% to $2.69 billion. Free cash flow hit $915 million, non-GAAP operating margin expanded to 13.3% from 8.0%, and management hiked full-year non-GAAP EPS guidance to $3.35 to $3.45, up from a prior $2.30 to $2.50 range. CEO Antonio Neri framed it plainly: “HPE delivered an exceptional quarter with record-breaking revenue, higher-than-anticipated profitability, and increased free cash flow.”
Error: Invalid chart data JSON
The stock is up 90.1% since March 31, 2026 and 126.21% over one year. Yet our model still flags 16.09% base case upside to $53.31, the analyst target sits at $64.13, and composite sentiment reads bullish at 69.26. Screens as a Buy, and Elliott’s involvement is far from finished.
The Takeaway Singer’s five-name book is a spectrum, not a basket. HPE and TFPM screen as buys with real modeled upside. Phillips 66 has run past the activist thesis and now screens as a sell. Suncor and Southwest are compounders that already delivered the easy dollars. If you are trailing Elliott into these names, the sequence matters more than the ticker list. The window on the two still-open trades is not going to stay open forever.
Act now: the analyst who called NVIDIA in 2010 just named his top 10 AI stocks — and Phillips 66 didn't make the cut. Grab the names FREE today.
Momentum investing revolves around the idea of following a stock's recent trend in either direction. In "long context," investors will be essentially be "buying high, but hoping to sell even higher." With this methodology, taking advantage of trends in a stock's price is key; once a stock establishes a course, it is more than likely to continue moving that way. The goal is that once a stock heads down a fixed path, it will lead to timely and profitable trades.
Even though momentum is a popular stock characteristic, it can be tough to define. Debate surrounding which are the best and worst metrics to focus on is lengthy, but the Zacks Momentum Style Score, part of the Zacks Style Scores, helps address this issue for us.
Below, we take a look at CSX (CSX - Free Report) , which currently has a Momentum Style Score of A. We also discuss some of the main drivers of the Momentum Style Score, like price change and earnings estimate revisions.
It's also important to note that Style Scores work as a complement to the Zacks Rank, our stock rating system that has an impressive track record of outperformance. CSX currently has a Zacks Rank of #2 (Buy). Our research shows that stocks rated Zacks Rank #1 (Strong Buy) and #2 (Buy) and Style Scores of "A or B" outperform the market over the following one-month period.
You can see the current list of Zacks #1 Rank Stocks here >>>
Set to Beat the Market? In order to see if CSX is a promising momentum pick, let's examine some Momentum Style elements to see if this freight railroad holds up.
Looking at a stock's short-term price activity is a great way to gauge if it has momentum, since this can reflect both the current interest in a stock and if buyers or sellers have the upper hand at the moment. It's also helpful to compare a security to its industry; this can show investors the best companies in a particular area.
For CSX, shares are up 2.71% over the past week while the Zacks Transportation - Rail industry is up 3.42% over the same time period. Shares are looking quite well from a longer time frame too, as the monthly price change of 11.32% compares favorably with the industry's 7.12% performance as well.
While any stock can see its price increase, it takes a real winner to consistently beat the market. That is why looking at longer term price metrics -- such as performance over the past three months or year -- can be useful as well. Shares of CSX have increased 16.25% over the past quarter, and have gained 50.89% in the last year. In comparison, the S&P 500 has only moved 4.48% and 17.65%, respectively.
Investors should also take note of CSX's average 20-day trading volume. Volume is a useful item in many ways, and the 20-day average establishes a good price-to-volume baseline; a rising stock with above average volume is generally a bullish sign, whereas a declining stock on above average volume is typically bearish. Right now CSX is averaging 12,499,395 shares for the last 20 days..
Earnings OutlookThe Zacks Momentum Style Score also takes into account trends in estimate revisions, in addition to price changes. Please note that estimate revision trends remain at the core of Zacks Rank as well. A nice path here can help show promise, and we have recently been seeing that with CSX.
Over the past two months, 5 earnings estimates moved higher compared to none lower for the full year. These revisions helped boost CSX's consensus estimate, increasing from $1.90 to $1.94 in the past 60 days. Looking at the next fiscal year, 6 estimates have moved upwards while there have been no downward revisions in the same time period.
Bottom LineGiven these factors, it shouldn't be surprising that CSX is a #2 (Buy) stock and boasts a Momentum Score of A. If you're looking for a fresh pick that's set to soar in the near-term, make sure to keep CSX on your short list.
NEW YORK, July 24, 2026 (GLOBE NEWSWIRE) -- The Gross Law Firm issues the following notice to shareholders of Zoetis Inc. (NYSE: ZTS).
Shareholders who purchased shares of ZTS during the class period listed are encouraged to contact the firm regarding possible lead plaintiff appointment. Appointment as lead plaintiff is not required to partake in any recovery.
ALLEGATIONS: The complaint alleges that during the class period, Defendants issued materially false and/or misleading statements and/or failed to disclose that: (i) veterinarian prescription growth and adoption of Zoetis’ Librela, a canine pain treatment, were sharply weakening as clinicians became more cautious following FDA safety warnings concerning serious neurological complications in dogs; (ii) Zoetis’ Simparica Trio was losing significant market share to a lower priced competing canine parasiticide with broader indicated use in a slowing overall market; and (iii) Zoetis’ dermatology products, Apoquel and Cytopoint, were losing substantial market share to a newly launched competing canine treatment.
DEADLINE: July 27, 2026 Shareholders should not delay in registering for this class action. Register your information here: https://securitiesclasslaw.com/securities/zoetis-inc-loss-submission-form-2/?id=195836&from=3
NEXT STEPS FOR SHAREHOLDERS: Once you register as a shareholder who purchased shares of ZTS during the timeframe listed above, you will be enrolled in a portfolio monitoring software to provide you with status updates throughout the lifecycle of the case. The deadline to seek to be a lead plaintiff is July 27, 2026. There is no cost or obligation to you to participate in this case.
WHY GROSS LAW FIRM? The Gross Law Firm is a nationally recognized class action law firm, and our mission is to protect the rights of all investors who have suffered as a result of deceit, fraud, and illegal business practices. The Gross Law Firm is committed to ensuring that companies adhere to responsible business practices and engage in good corporate citizenship. The firm seeks recovery on behalf of investors who incurred losses when false and/or misleading statements or the omission of material information by a company lead to artificial inflation of the company's stock. Attorney advertising. Prior results do not guarantee similar outcomes.
CONTACT:
The Gross Law Firm
15 West 38th Street, 12th floor
New York, NY, 10018
Email: [email protected]
Phone: (646) 453-8903
Corteva, Inc. (CTVA - Free Report) could be a solid choice for investors given its recent upgrade to a Zacks Rank #2 (Buy). This rating change essentially reflects an upward trend in earnings estimates -- one of the most powerful forces impacting stock prices.
The sole determinant of the Zacks rating is a company's changing earnings picture. The Zacks Consensus Estimate -- the consensus of EPS estimates from the sell-side analysts covering the stock -- for the current and following years is tracked by the system.
Since a changing earnings picture is a powerful factor influencing near-term stock price movements, the Zacks rating system is very useful for individual investors. They may find it difficult to make decisions based on rating upgrades by Wall Street analysts, as these are mostly driven by subjective factors that are hard to see and measure in real time.
As such, the Zacks rating upgrade for Corteva, Inc. is essentially a positive comment on its earnings outlook that could have a favorable impact on its stock price.
Most Powerful Force Impacting Stock PricesThe change in a company's future earnings potential, as reflected in earnings estimate revisions, has proven to be strongly correlated with the near-term price movement of its stock. That's partly because of the influence of institutional investors that use earnings and earnings estimates for calculating the fair value of a company's shares. An increase or decrease in earnings estimates in their valuation models simply results in higher or lower fair value for a stock, and institutional investors typically buy or sell it. Their transaction of large amounts of shares then leads to price movement for the stock.
Fundamentally speaking, rising earnings estimates and the consequent rating upgrade for Corteva, Inc. imply an improvement in the company's underlying business. Investors should show their appreciation for this improving business trend by pushing the stock higher.
Harnessing the Power of Earnings Estimate RevisionsEmpirical research shows a strong correlation between trends in earnings estimate revisions and near-term stock movements, so it could be truly rewarding if such revisions are tracked for making an investment decision. Here is where the tried-and-tested Zacks Rank stock-rating system plays an important role, as it effectively harnesses the power of earnings estimate revisions.
The Zacks Rank stock-rating system, which uses four factors related to earnings estimates to classify stocks into five groups, ranging from Zacks Rank #1 (Strong Buy) to Zacks Rank #5 (Strong Sell), has an impressive externally-audited track record, with Zacks Rank #1 stocks generating an average annual return of +25% since 1988. You can see the complete list of today's Zacks #1 Rank (Strong Buy) stocks here >>>> .
Earnings Estimate Revisions for Corteva, Inc.For the fiscal year ending December 2026, this agriculture is expected to earn $3.76 per share, which is unchanged compared with the year-ago reported number.
Analysts have been steadily raising their estimates for Corteva, Inc.. Over the past three months, the Zacks Consensus Estimate for the company has increased 3.7%.
Bottom LineUnlike the overly optimistic Wall Street analysts whose rating systems tend to be weighted toward favorable recommendations, the Zacks rating system maintains an equal proportion of "buy" and "sell" ratings for its entire universe of more than 4,000 stocks at any point in time. Irrespective of market conditions, only the top 5% of the Zacks-covered stocks get a "Strong Buy" rating and the next 15% get a "Buy" rating. So, the placement of a stock in the top 20% of the Zacks-covered stocks indicates its superior earnings estimate revision feature, making it a solid candidate for producing market-beating returns in the near term.
You can learn more about the Zacks Rank here >>>
The upgrade of Corteva, Inc. to a Zacks Rank #2 positions it in the top 20% of the Zacks-covered stocks in terms of estimate revisions, implying that the stock might move higher in the near term.
2 Canadian Mid-Cap Dividend Payers Energized For GrowthOvintiv NYSE: OVV reported second-quarter 2026 free cash flow of $682 million and cash flow per share of $4.46, with both measures exceeding consensus estimates, according to executives on the company’s earnings call. The company also raised its full-year oil and condensate production outlook after production from its Permian operations surpassed expectations.
President and CEO Brendan McCracken said the company generated more than $1.3 billion in free cash flow during the first half of the year and returned approximately 63% of second-quarter free cash flow to shareholders through share repurchases and its base dividend. Ovintiv expects full-year shareholder returns to exceed 60%, following returns of about 45% year to date.
Get Ovintiv alerts:
Production Guidance Raised on Permian Outperformance Second-quarter oil and condensate production averaged 206,000 barrels per day, above the high end of Ovintiv’s guidance, while total production was 615,000 barrels of oil equivalent per day. Chief Financial Officer Corey Code said the production beat was driven by both new-well productivity and stronger-than-expected base production in the Permian Basin.
The company raised its full-year oil and condensate production guidance to between 210,000 and 212,000 barrels per day. Ovintiv also increased the go-forward Permian oil production run rate to 125,000 barrels per day from 120,000 barrels per day previously, without adding capital spending or drilling activity.
Code said the revised outlook, combined with year-to-date repurchases, represents about 4% oil production growth on a per-share basis. Ovintiv maintained its full-year capital guidance and expects third-quarter capital spending of approximately $575 million, in line with second-quarter spending. Third-quarter total production is expected to average roughly 628,000 BOE per day, including about 208,000 barrels per day of oil and condensate.
Natural gas production came in below guidance during the quarter because of planned Montney plant turnarounds, although Ovintiv said the revenue impact was limited by weak AECO natural gas prices. The company maintained the midpoint of its prior full-year natural gas outlook at 2.05 billion cubic feet per day and increased full-year NGL guidance to about 84,000 barrels per day.
Debt Reduction and Buyback Focus Ovintiv reduced net debt by about $3.4 billion during the quarter, using proceeds from its Anadarko disposition and a portion of free cash flow. Quarter-end net debt stood at $2.995 billion, resulting in a leverage ratio of 0.6 times.
Code said the lower debt balance represented a key milestone for the company, while Fitch upgraded Ovintiv’s credit rating to BBB from BBB low. McCracken said the company views its capital structure as appropriately sized and plans to balance additional debt reduction, share repurchases and smaller land-focused transactions.
During the question-and-answer session, McCracken said Ovintiv sees value in repurchasing shares but does not have a “crystal ball” on commodity prices. He said the company expects its “ground game” acquisitions to be in the low hundreds of millions of dollars range and focused on modest-sized deals in the Permian and Montney.
Operational Technology and Montney Developments Chief Operating Officer Greg Givens attributed Permian outperformance to improved new-well results, base-production optimization and the company’s development approach, which includes co-developing stacked zones from a single pad and timing adjacent development projects to limit pressure depletion.
Givens said Ovintiv has completed approximately 400 Permian wells with surfactant treatments since 2019 and has seen about a 9% improvement in oil productivity compared with wells that did not receive the treatment. The company estimates the surfactants account for roughly half of its productivity uplift over the past several years. Ovintiv said the treatment costs about $100,000 per well.
The company is beginning to evaluate surfactant use in the Montney, where McCracken said it remains in the early stages. Ovintiv also cited the use of AI, automation and its Permian Operations Control Center as contributors to reduced downtime, improved artificial-lift performance and stronger base production.
In the Montney, planned plant turnarounds were completed in the second quarter. Ovintiv said it prioritized production from its most liquids-rich wells during the outages, limiting the effect on condensate volumes. Based on current strip prices, the company expects second-half Montney condensate production of 80,000 to 85,000 barrels per day.
Canadian condensate realizations averaged about $94 per barrel during the quarter, at a premium to WTI, Givens said. Ovintiv also reported that its Montney gas realization was 187% of AECO, supported by physical sales arrangements, financial contracts and approximately $40 million of sulfur revenue. Sulfur, a byproduct from certain Montney gas operations, benefited from historically high prices during the period.
Inventory, Sand Supply and Market Access McCracken said Ovintiv has added more than 3,200 Permian and Montney drilling locations since 2023 at an average cost of $1.4 million per net 10,000-foot location. The company estimates it has nearly 15 years of premium inventory in the Permian and close to 20 years of premium oil inventory in the Montney.
Ovintiv said it has already replaced its planned 2026 drilling locations in both regions through organic additions. In the Permian, the company is evaluating approximately 100,000 acres of Barnett potential on acreage it has held for more than a decade. Givens said Ovintiv has drilled and cored the vertical section of its first Barnett well in Martin County and expects the well to begin production late this year.
In the Montney, Ovintiv said completion speeds have averaged more than 4,900 feet per day year to date, about 20% faster than its 2023 pace. The company recently completed more than 7,000 lateral feet per day in a simul-frac operation and completed Canada’s first 100% domestic wet-sand pad, according to management. Domestic wet sand is roughly 20% less expensive than imported dry sand, the company said, though Ovintiv expects broader adoption to depend on local supply infrastructure and could take until around 2028.
Management also said it continues to diversify its natural-gas pricing away from AECO and Waha. Ovintiv reported total company gas price realizations, including hedging, of $1.99 per Mcf during the quarter, or about 70% of NYMEX pricing.
About Ovintiv (NYSE:OVV)Ovintiv Inc is a North American energy company focused on the exploration, development and production of oil, natural gas and natural gas liquids. Formerly known as Encana Corporation, the company rebranded as Ovintiv in January 2020 and established its headquarters in Denver, Colorado. Ovintiv's upstream portfolio spans multiple unconventional resource plays, reflecting a strategy centered on high-return projects and disciplined capital allocation.
The company's core business activities include the acquisition and development of acreage in major shale basins across the United States and Canada.
This instant news alert was generated by narrative science technology and financial data from MarketBeat in order to provide readers with the fastest reporting and unbiased coverage. Please send any questions or comments about this story to [email protected].
Should You Invest $1,000 in Ovintiv Right Now?Before you consider Ovintiv, you'll want to hear this.
MarketBeat keeps track of Wall Street's top-rated and best performing research analysts and the stocks they recommend to their clients on a daily basis. MarketBeat has identified the five stocks that top analysts are quietly whispering to their clients to buy now before the broader market catches on... and Ovintiv wasn't on the list.
While Ovintiv currently has a Moderate Buy rating among analysts, top-rated analysts believe these five stocks are better buys.
View The Five Stocks Here
Enter your email address and we’ll send you MarketBeat’s list of ten stocks set to soar in Summer 2026, despite the threat of tariffs and what's happening in Iran. These ten stocks are incredibly resilient and are likely to thrive in any economic environment.
Shares of Tesla (NASDAQ:TSLA | TSLA Price Prediction) are trading at $308.05 in Friday afternoon action, down 4% on the day and 18% over the past month.
A logo of Blackstone is pictured in Manhattan, New York City, U.S. July 29, 2025. REUTERS/Mike Segar/File Photo Purchase Licensing Rights, opens new tab
SummaryCompaniesBidding for MarineMax has moved into third roundDonerail, Blackstone, Centerbridge among interested partiesInvestment firm Donerail began pushing for a sale last yearNEW YORK, July 24 (Reuters) - Investment firms Blackstone (BX.N), opens new tab and Donerail are among the final bidders to acquire MarineMax (HZO.N), opens new tab, two people familiar with the matter said on Friday, as the recreational yacht retailer explores selling itself.
The two, as well as private equity firm Centerbridge, are in the final round of bidding for the Clearwater, Florida-headquartered company, said the sources who are not permitted to discuss private deliberations.
The Reuters Daily Briefing newsletter provides all the news you need to start your day. Sign up here.
MarineMax, which has a market value of around $725 million, caters to a wealthy clientele through its 65 marinas and storage locations and 70 dealerships, mostly in the U.S. It has attracted significant interest at a time the marina business has become a popular investment area.
Donerail began pushing MarineMax to sell itself or replace its chief executive officer last year, intensifying pressure on the company after Levin Capital in 2024 urged management and the board to evaluate strategic alternatives.
Representatives for MarineMax, Blackstone, and Donerail declined to comment. A representative for Centerbridge did not immediately respond to a comment request.
The company has made some changes aimed at addressing concerns of disgruntled investors, including replacing board directors, but has never publicly acknowledged running a sales process including on Thursday when it reported quarterly earnings.
Reuters reported in February that Donerail submitted an all-cash offer which valued MarineMax at around $1 billion. Donerail subsequently raised its offer, while other buyout firms including Blackstone jumped into the mix as the company formally solicited buyer interest from April onwards.
Marinas and superyacht services have seen significant dealmaking in the last 18 months, with investment firms being particularly active.
Lower interest rates have supported high-end consumers' spending on luxury items like yachts even as other economic brackets are forced to tighten their belts.
Blackstone, through its infrastructure arm, bought Safe Harbor Marinas in 2025 for $5.7 billion. Fellow infrastructure investor Stonepeak acquired marina owner and operator Southern Marinas in April.
MarineMax was trading around $33.30 per share around midday on Friday, putting year-to-date gains around 37%. However, it is still trading at roughly half the value of its lifetime high hit in May 2021.
Reporting by Svea Herbst-Bayliss; Editing by David French and Sanjeev Miglani
Our Standards: The Thomson Reuters Trust Principles., opens new tab
Key Takeaways Chipotle is set to report Q2 2026 on July 29, with consensus EPS of 32 cents and revenues of $3.32B.CMG may benefit from Honey Chicken, Cilantro Lime Sauce and stronger Rewards enrollment in Q2.Chipotle likely faces margin pressure from higher avocado, dairy, beef and labor costs in Q2. Chipotle Mexican Grill, Inc. (CMG - Free Report) is scheduled to report second-quarter 2026 results on July 29.
CMG’s earnings beat the Zacks Consensus Estimate in each of the trailing four quarters, the average surprise being 2.7%.
Trend in the Estimate Revision of CMGThe Zacks Consensus Estimate for second-quarter earnings per share (EPS) is pegged at 32 cents, indicating a decline of 3% from 33 cents reported in the year-ago quarter.
For revenues, the consensus mark is pegged at $3.32 billion. The metric suggests a rise of 8.4% from the year-ago quarter’s figure.
Let us take a look at how things might have shaped up in the quarter to be reported.
Factors Likely to Shape CMG’s Quarterly ResultsChipotle’s second-quarter performance is likely to have been supported by menu innovation, stronger customer engagement and continued restaurant expansion. The company anticipated comparable restaurant sales growth of approximately 1% in the quarter under review. Menu pricing of about 1.5% and a broadly flat sales mix are also expected to have supported the top line. The return of Chipotle Honey Chicken and continued demand for Cilantro Lime Sauce are likely to have aided transactions and average check.
The refreshed Chipotle Rewards program is expected to have supported customer acquisition, re-engagement and visit frequency. Following the program’s April relaunch, the company recorded a nearly 25% increase in daily enrollments. The continued rollout of high-efficiency equipment is likely to have aided CMG’s performance in the second quarter.
However, elevated input costs are likely to have pressured profitability. Chipotle anticipated cost of sales of approximately 30% of revenues in the quarter to be reported, reflecting mid-single-digit inflation and higher avocado, dairy and beef costs. Labor costs were expected to remain in the low-25% range, with wage inflation in the low-single digits.
Continued investments in technology, personnel and restaurant operations are also likely to have constrained margin expansion in the to-be-reported quarter. Our model predicts second-quarter restaurant-level margins to decline 240 basis points year over year to 25%.
What Our Model Says About CMG StockOur proven model predicts an earnings beat for Chipotle this time around. The combination of a positive Earnings ESP and a Zacks Rank #1 (Strong Buy), 2 (Buy) or 3 (Hold) increases the odds of an earnings beat, which is exactly the case here.
Earnings ESP for CMG: Chipotle has an Earnings ESP of +0.84%. You can uncover the best stocks to buy or sell before they’re reported with our Earnings ESP Filter.
Chipotle’s Zacks Rank: The company currently carries a Zacks Rank #3.
Other Stocks With the Favorable CombinationHere are a few other stocks from the Zacks Retail-Wholesale sector, which, according to our model, also have the right combination of elements to post an earnings beat this reporting cycle.
BJ's Restaurants, Inc. (BJRI - Free Report) currently has an Earnings ESP of +7.51% and a Zacks Rank of 2. You can see the complete list of today’s Zacks #1 Rank stocks here.
In the to-be-reported quarter, BJRI’s earnings are expected to decline 10.3%. BJRI’s earnings beat the Zacks Consensus Estimate in three of the trailing four quarters and missed on one occasion, the average surprise being 136%.
Sweetgreen, Inc. (SG - Free Report) has an Earnings ESP of +11.54% and a Zacks Rank of 2 at present.
In the to-be-reported quarter, Sweetgreen’s earnings are expected to register a 35% year-over-year increase. Sweetgreen’s earnings missed estimates in each of the trailing four quarters, the average miss being 42.4%.
The Cheesecake Factory Incorporated (CAKE - Free Report) currently has an Earnings ESP of +2.76% and a Zacks Rank of 3.
In the to-be-reported quarter, Cheesecake Factory’s earnings are expected to register a 0.9% year-over-year increase. CAKE’s earnings surpassed estimates in each of the trailing four quarters, the average surprise being 6.7%.
BALA CYNWYD, Pa., July 24, 2026 (GLOBE NEWSWIRE) -- Brodsky & Smith reminds investors of the following investigations. If you own shares and wish to discuss the investigation, contact Jason Brodsky ([email protected]) or Marc Ackerman ([email protected]) at 855-576-4847. There is no cost or financial obligation to you.
Momentum investing revolves around the idea of following a stock's recent trend in either direction. In "long context," investors will be essentially be "buying high, but hoping to sell even higher." With this methodology, taking advantage of trends in a stock's price is key; once a stock establishes a course, it is more than likely to continue moving that way. The goal is that once a stock heads down a fixed path, it will lead to timely and profitable trades.
Even though momentum is a popular stock characteristic, it can be tough to define. Debate surrounding which are the best and worst metrics to focus on is lengthy, but the Zacks Momentum Style Score, part of the Zacks Style Scores, helps address this issue for us.
Below, we take a look at PBF Energy (PBF - Free Report) , a company that currently holds a Momentum Style Score of A. We also talk about price change and earnings estimate revisions, two of the main aspects of the Momentum Style Score.
It's also important to note that Style Scores work as a complement to the Zacks Rank, our stock rating system that has an impressive track record of outperformance. PBF Energy currently has a Zacks Rank of #1 (Strong Buy). Our research shows that stocks rated Zacks Rank #1 (Strong Buy) and #2 (Buy) and Style Scores of "A or B" outperform the market over the following one-month period.
You can see the current list of Zacks #1 Rank Stocks here >>>
Set to Beat the Market? In order to see if PBF is a promising momentum pick, let's examine some Momentum Style elements to see if this refiner holds up.
Looking at a stock's short-term price activity is a great way to gauge if it has momentum, since this can reflect both the current interest in a stock and if buyers or sellers have the upper hand at the moment. It is also useful to compare a security to its industry, as this can help investors pinpoint the top companies in a particular area.
For PBF, shares are up 18% over the past week while the Zacks Oil and Gas - Refining and Marketing industry is up 9.82% over the same time period. Shares are looking quite well from a longer time frame too, as the monthly price change of 46.49% compares favorably with the industry's 20.2% performance as well.
While any stock can see a spike in price, it takes a real winner to consistently outperform the market. Shares of PBF Energy have increased 42.87% over the past quarter, and have gained 165.54% in the last year. In comparison, the S&P 500 has only moved 4.48% and 17.65%, respectively.
Investors should also take note of PBF's average 20-day trading volume. Volume is a useful item in many ways, and the 20-day average establishes a good price-to-volume baseline; a rising stock with above average volume is generally a bullish sign, whereas a declining stock on above average volume is typically bearish. Right now PBF is averaging 3,021,517 shares for the last 20 days..
Earnings OutlookThe Zacks Momentum Style Score encompasses many things, including estimate revisions and a stock's price movement. Investors should note that earnings estimates are also significant to the Zacks Rank, and a nice path here can be promising. We have recently been noticing this with PBF.
Over the past two months, 4 earnings estimates moved higher compared to none lower for the full year. These revisions helped boost PBF's consensus estimate, increasing from $6.99 to $10.94 in the past 60 days. Looking at the next fiscal year, 5 estimates have moved upwards while there have been no downward revisions in the same time period.
Bottom LineGiven these factors, it shouldn't be surprising that PBF is a #1 (Strong Buy) stock and boasts a Momentum Score of A. If you're looking for a fresh pick that's set to soar in the near-term, make sure to keep PBF Energy on your short list.
Have you been searching for a stock that might be well-positioned to maintain its earnings-beat streak in its upcoming report? It is worth considering Permian Resources (PR - Free Report) , which belongs to the Zacks Oil and Gas - Exploration and Production - United States industry.
When looking at the last two reports, this company has recorded a strong streak of surpassing earnings estimates. The company has topped estimates by 17.39%, on average, in the last two quarters.
For the last reported quarter, Permian Resources came out with earnings of $0.39 per share versus the Zacks Consensus Estimate of $0.38 per share, representing a surprise of 2.63%. For the previous quarter, the company was expected to post earnings of $0.28 per share and it actually produced earnings of $0.37 per share, delivering a surprise of 32.14%.
Price and EPS Surprise
Thanks in part to this history, there has been a favorable change in earnings estimates for Permian Resources lately. In fact, the Zacks Earnings ESP (Expected Surprise Prediction) for the stock is positive, which is a great indicator of an earnings beat, particularly when combined with its solid Zacks Rank.
Our research shows that stocks with the combination of a positive Earnings ESP and a Zacks Rank #3 (Hold) or better produce a positive surprise nearly 70% of the time. In other words, if you have 10 stocks with this combination, the number of stocks that beat the consensus estimate could be as high as seven.
The Zacks Earnings ESP compares the Most Accurate Estimate to the Zacks Consensus Estimate for the quarter; the Most Accurate Estimate is a version of the Zacks Consensus whose definition is related to change. The idea here is that analysts revising their estimates right before an earnings release have the latest information, which could potentially be more accurate than what they and others contributing to the consensus had predicted earlier.
Permian Resources currently has an Earnings ESP of +0.77%, which suggests that analysts have recently become bullish on the company's earnings prospects. This positive Earnings ESP when combined with the stock's Zacks Rank #3 (Hold) indicates that another beat is possibly around the corner. We expect the company's next earnings report to be released on August 5, 2026.
When the Earnings ESP comes up negative, investors should note that this will reduce the predictive power of the metric. But, a negative value is not indicative of a stock's earnings miss.
Many companies end up beating the consensus EPS estimate, but that may not be the sole basis for their stocks moving higher. On the other hand, some stocks may hold their ground even if they end up missing the consensus estimate.
Because of this, it's really important to check a company's Earnings ESP ahead of its quarterly release to increase the odds of success. Make sure to utilize our Earnings ESP Filter to uncover the best stocks to buy or sell before they've reported.
A month has gone by since the last earnings report for Jefferies (JEF - Free Report) . Shares have added about 5.6% in that time frame, outperforming the S&P 500.
But investors have to be wondering, will the recent positive trend continue leading up to its next earnings release, or is Jefferies due for a pullback? Before we dive into how investors and analysts have reacted as of late, let's take a quick look at the most recent earnings report in order to get a better handle on the important catalysts.
Jefferies Q2 Earnings Miss Estimates Despite Record IB PerformanceJefferies’ second-quarter fiscal 2026 (ended May 31) adjusted earnings per share from continuing operations of $1.03 missed the Zacks Consensus Estimate of $1.09. However, the bottom line increased significantly from the prior-year quarter.
Results were primarily aided by record IB advisory and underwriting net revenues, as well as record equities net revenues. However, a rise in expenses hurt the results to an extent.
Net earnings attributable to common shareholders (GAAP) increased significantly year over year from $88 million to $226.2 million.
Revenues Improve, Expenses RiseQuarterly net revenues were $2.21 billion, up 35% from the prior-year quarter. The top line marginally missed the Zacks Consensus Estimate of $2.22 billion.
Total non-interest expenses were $1.89 billion, up 26.1% from the year-ago quarter. The rise was due to an increase in almost all cost components, except for depreciation and amortization costs, cost of sales, and other expenses.
As of May 31, 2026, book value per common share was $51.95, up from $49.96 as of May 31, 2025. Furthermore, adjusted tangible book value per fully diluted share increased from $32.84 to $34.55.
Quarterly Segment PerformanceInvestment Banking & Capital Markets: Total Net revenues were $2.01 billion, rising 36.4% from the prior-year quarter. Investment Banking net revenues were $1.21 billion, up 57.5% year over year, driven by higher advisory and equity underwriting revenues, while debt underwriting remained solid but declined year over year. Capital Markets net revenues were $799.3 million, up 13.5%, driven by increases in both Equities and Fixed Income net revenues.
Asset Management: Net revenues were $187.7 million, up 21.4% from the year-ago quarter. Asset management fees and revenues, as well as investment return, declined year over year, but other investments, inclusive of net interest, increased.
Balance Sheet SolidAs of May 31, 2026, total assets were $79.54 billion, up from $74.38 billion as of Feb. 28, 2026, while total shareholders’ equity was $10.57 billion, down modestly from $10.61 billion.
The leverage ratio was 7.5 compared with 6.5 in the prior-year quarter, and the tangible gross leverage ratio was 9.0 compared with 7.9.
Return on adjusted tangible shareholders’ equity was 12.8%, up from 5.5% in the prior-year quarter.
Share Repurchase UpdateIn the reported quarter, Jefferies repurchased 4 million common shares for $197 million, at an average price of $49.83 per share.
How Have Estimates Been Moving Since Then?In the past month, investors have witnessed a downward trend in fresh estimates.
The consensus estimate has shifted -8.9% due to these changes.
VGM ScoresCurrently, Jefferies has a strong Growth Score of A, though it is lagging a lot on the Momentum Score front with an F. However, the stock has a grade of B on the value side, putting it in the top 40% for this investment strategy.
Overall, the stock has an aggregate VGM Score of B. If you aren't focused on one strategy, this score is the one you should be interested in.
OutlookEstimates have been broadly trending downward for the stock, and the magnitude of these revisions indicates a downward shift. Notably, Jefferies has a Zacks Rank #3 (Hold). We expect an in-line return from the stock in the next few months.
Momentum investing is all about the idea of following a stock's recent trend, which can be in either direction. In the "long context," investors will essentially be "buying high, but hoping to sell even higher." And for investors following this methodology, taking advantage of trends in a stock's price is key; once a stock establishes a course, it is more than likely to continue moving in that direction. The goal is that once a stock heads down a fixed path, it will lead to timely and profitable trades.
While many investors like to look for momentum in stocks, this can be very tough to define. There is a lot of debate surrounding which metrics are the best to focus on and which are poor quality indicators of future performance. The Zacks Momentum Style Score, part of the Zacks Style Scores, helps address this issue for us.
Below, we take a look at Terreno Realty (TRNO - Free Report) , a company that currently holds a Momentum Style Score of B. We also talk about price change and earnings estimate revisions, two of the main aspects of the Momentum Style Score.
It's also important to note that Style Scores work as a complement to the Zacks Rank, our stock rating system that has an impressive track record of outperformance. Terreno Realty currently has a Zacks Rank of #2 (Buy). Our research shows that stocks rated Zacks Rank #1 (Strong Buy) and #2 (Buy) and Style Scores of "A or B" outperform the market over the following one-month period.
You can see the current list of Zacks #1 Rank Stocks here >>>
Set to Beat the Market? In order to see if TRNO is a promising momentum pick, let's examine some Momentum Style elements to see if this industrial real estate company holds up.
Looking at a stock's short-term price activity is a great way to gauge if it has momentum, since this can reflect both the current interest in a stock and if buyers or sellers have the upper hand at the moment. It's also helpful to compare a security to its industry; this can show investors the best companies in a particular area.
For TRNO, shares are up 8.16% over the past week while the Zacks REIT and Equity Trust - Other industry is up 3.41% over the same time period. Shares are looking quite well from a longer time frame too, as the monthly price change of 10.27% compares favorably with the industry's 2.1% performance as well.
While any stock can see its price increase, it takes a real winner to consistently beat the market. That is why looking at longer term price metrics -- such as performance over the past three months or year -- can be useful as well. Over the past quarter, shares of Terreno Realty have risen 10.52%, and are up 25.91% in the last year. In comparison, the S&P 500 has only moved 4.48% and 17.65%, respectively.
Investors should also pay attention to TRNO's average 20-day trading volume. Volume is a useful item in many ways, and the 20-day average establishes a good price-to-volume baseline; a rising stock with above average volume is generally a bullish sign, whereas a declining stock on above average volume is typically bearish. TRNO is currently averaging 1,109,706 shares for the last 20 days.
Earnings OutlookThe Zacks Momentum Style Score encompasses many things, including estimate revisions and a stock's price movement. Investors should note that earnings estimates are also significant to the Zacks Rank, and a nice path here can be promising. We have recently been noticing this with TRNO.
Over the past two months, 2 earnings estimates moved higher compared to none lower for the full year. These revisions helped boost TRNO's consensus estimate, increasing from $2.79 to $2.81 in the past 60 days. Looking at the next fiscal year, 2 estimates have moved upwards while there have been no downward revisions in the same time period.
Bottom LineTaking into account all of these elements, it should come as no surprise that TRNO is a #2 (Buy) stock with a Momentum Score of B. If you've been searching for a fresh pick that's set to rise in the near-term, make sure to keep Terreno Realty on your short list.
Key Takeaways Crocs brand, DTC and international growth are expected to support second-quarter sales and earnings.HEYDUDE faces continued pressure from weak U.S. demand, tariffs and wholesale channel resets.CROX's earnings outlook is tempered by a Sell Rank despite attractive valuation and recent share gains. Crocs, Inc. (CROX - Free Report) is scheduled to release second-quarter 2026 results on July 30, before market open. The Zacks Consensus Estimate for revenues is pegged at $1.2 billion, indicating a drop of 0.2% from the prior-year figure.
The consensus estimate for earnings per share has risen a couple of cents in the past seven days to $4.32. The estimate indicates a rise of 2.1% from the year-ago period’s number.
The Broomfield, CO-based company has a trailing four-quarter earnings surprise of 13.6%, on average. In the last reported quarter, its bottom line surpassed the Zacks Consensus Estimate by 7.6%.
Key Factors to Note Ahead of CROX’s ResultsCrocs’ quarterly results are likely to reflect gains from brand strength, consumer demand and the strength of its core product categories, including clogs and sandals. The company has consistently performed well in these segments, supported by effective pricing strategies and strong brand appeal. Its personalization engine, particularly the Jibbitz business, has also shown steady growth.
Additionally, Crocs' solid performance in its direct-to-consumer (DTC) channel and international division is expected to have further offered a boost. The Zacks Consensus Estimate for the company’s DTC and international revenues is currently pegged at $646 million and $546 million, respectively, showing corresponding increases of 10.4% and 8.8% from the year-ago period.
However, the company has been witnessing persistent softness in its HEYDUDE brand, which, coupled with a tough macroeconomic environment, is likely to have negatively impacted sales. Crocs’ HEYDUDE brand continues to face headwinds, with softness due to cautious U.S. consumer, elevated tariffs and wholesale channel pressures. The brand is navigating a prolonged reset in North America, marked by incremental inventory returns, wholesale cleanups and a pullback in performance marketing to improve profitability.
On its last earnings call, management had expected revenues to fall slightly year over year at currency rates as of April 27, 2026, with the Crocs brand up 1-3% and HEYDUDE down 14-12% from the second-quarter 2025 actuals. It had anticipated adjusted operating margin of 24.7% and adjusted earnings of $4.15-$4.35 per share. The consensus mark for the company’s HEYDUDE brand’s revenues is currently pegged at $167 million, indicating a decline of 12.1% from the year-ago period.
What Our Zacks Model Unveils for CrocsOur proven model does not conclusively predict an earnings beat for Crocs this season. The combination of a positive Earnings ESP and a Zacks Rank #1 (Strong Buy), 2 (Buy) or 3 (Hold) increases the odds of an earnings beat. But that’s not the case here. You can uncover the best stocks before they’re reported with our Earnings ESP Filter.
Crocs currently has an Earnings ESP of -0.12% and a Zacks Rank #4 (Sell).
CROX’s Valuation PictureFrom a valuation perspective, Crocs offers an attractive opportunity, trading at a discount relative to the historical and industry benchmarks. With a forward 12-month price-to-earnings ratio of 9.6X, which is below the five-year high of 21.6X and the Textile - Apparel industry’s average of 15.7X, the stock offers compelling value for investors seeking exposure to the sector.
The recent market movements show that Crocs’ shares have gained 29.7% in the past three months compared with the industry's 5.1% growth.
Stocks With the Favorable CombinationHere are some companies, which according to our model, have the right combination of elements to post an earnings beat:
SharkNinja, Inc. (SN - Free Report) currently has an Earnings ESP of +1.29% and a Zacks Rank of 2. You can see the complete list of today’s Zacks #1 Rank stocks here.
SN is likely to register bottom and top-line growth when it reports second-quarter 2026 results. The Zacks Consensus Estimate for its quarterly revenues is pegged at $1.6 billion, indicating a 13.5% increase from the figure reported in the year-ago quarter.
The consensus estimate for SN’s second-quarter earnings is pegged at $1.09 per share, implying 12.4% growth from the year-ago quarter’s actual. The consensus mark has dipped a penny in the past 30 days.
MGM Resorts International (MGM - Free Report) currently has an Earnings ESP of +0.08% and a Zacks Rank of 3. MGM is likely to register a top-line increase when it reports second-quarter 2026 results. The Zacks Consensus Estimate for its quarterly revenues is pegged at $4.5 billion, indicating a 1.5% rise from the figure reported in the year-ago quarter.
The consensus estimate for MGM Resorts’ second-quarter earnings is pegged at 60 cents a share, implying a 24.1% decrease from the year-earlier quarter. The consensus mark has been stable in the past 30 days.
Cintas Corporation (CTAS - Free Report) currently has an Earnings ESP of +0.09% and a Zacks Rank of 3. CTAS is likely to register bottom and top-line growth when it reports first-quarter fiscal 2027 results. The Zacks Consensus Estimate for its quarterly revenues is pegged at $3 billion, indicating 9.2% growth from the figure reported in the year-ago quarter.
The consensus estimate for CTAS first-quarter earnings is pegged at $1.35 a share, implying a 12.5% increase from the year-earlier quarter. The consensus mark has been stable in the past 30 days.
Key Takeaways CROX has outperformed peers recently but faces tariff, margin and HEYDUDE-related growth challenges.Crocs is investing in international expansion, marketing and inventory discipline to support long-term growth.CROX trades below the industry P/E but above its historical median valuation despite recent share gains. Crocs, Inc. (CROX - Free Report) has seen its shares rally 28.1% in the past three months, outperforming the industry’s growth of 5.6%. The stock has also outperformed the broader sector’s 4.7% decline and the S&P 500 Index’s 4% increase over the same period.
CROX Stock’s 3-Month Performance
Image Source: Zacks Investment Research
In the past three months, CROX has trailed the performance of Vince Holding Corp. (VNCE - Free Report) while outperforming G-III Apparel Group, Ltd. (GIII - Free Report) and Columbia Sportswear Company (COLM - Free Report) . In the same period, shares of VNCE, GIII and COLM have increased 31.5%, 8.8% and 1%, respectively.
CROX’s Share Price Performance VS Peers
Image Source: Zacks Investment Research
Closing at $132.47 in the last trading session, CROX stock stands 5.7% below its 52-week high of $140.42 reached on July 17, 2026. CROX is trading above its 50-day simple moving average of $120.99 and its 200-day simple moving average of $95.95, indicating a strong technical setup.
CROX Trades Above 50 & 200-Day SMA
Image Source: Zacks Investment Research
Crocs Drives Growth Through Global ExpansionCrocs remains optimistic about its international business, expecting strong growth across its international markets for the remainder of the year and seeing a multiyear runway for expansion in key markets. Management highlighted particularly robust performance in Japan and China, noting that both continue to deliver very strong growth and reinforce the company's long-term global opportunity.
To support future growth, the company is also investing in marketing across both brands to drive demand for new product launches. At the same time, Crocs is maintaining a disciplined approach to inventory and supply chain management, using lean inventory levels to improve productivity and enhance financial flexibility.
Crocs Reports Margin Pressure and Weak Brand PerformanceDespite these long-term growth opportunities, the company is facing the impact of the Middle East conflict and expects these impacts to create several challenges for the Crocs brand. Management identified three potential areas of impact: lower revenue from its Middle East distributor business, which has already been incorporated into its annual guidance; higher raw material and transportation costs associated with elevated oil prices; and the possibility of broader macroeconomic disruptions, the extent of which remains uncertain. These factors could create additional headwinds for the business going forward.
The company faced margin pressure in the first quarter of fiscal 2026, with enterprise adjusted gross margin declining 90 basis points year over year to 56.9%. The decrease was primarily driven by a 100-basis-point impact from incremental tariffs, along with an unfavorable product mix. These headwinds were only partially offset by a favorable brand mix, resulting in an overall decline in gross margin in the first quarter.
Crocs reported weaker performance across both of its key brands in the first quarter of fiscal 2026 while continuing to execute initiatives to return both brands to growth. Sales at the Crocs brand declined 2%, while the HEYDUDE brand recorded a steeper 13% decrease. Both brands reported lower adjusted gross margins in the quarter. Adjusted gross margin for the Crocs brand declined 120 basis points to 59.5%, while the HEYDUDE brand experienced a steeper contraction of 210 basis points, bringing its adjusted gross margin to 44.5%.
Crocs issued a cautious outlook, expecting second-quarter revenues to decline slightly at prevailing currency rates, with continued weakness at the HEYDUDE brand and margin pressure from tariffs. For 2026, the company projects muted enterprise revenue growth between down 1% and up 1%, while HEYDUDE is still expected to post a 5% to 7% sales decline despite an improved outlook.
How Estimates Are Shaped Up for CROX?The Zacks Consensus Estimate for CROX’s current quarter earnings per share has been revised up by 2 cents to $4.32 in the past seven days. The consensus mark for the current year earnings per share has been revised down by a penny to $13.66, reflecting a challenging outlook for the year.
Image Source: Zacks Investment Research
CROX is currently trading at a forward 12-month P/E multiple of 9.29X, lower than the industry average of 15.70X and well below the S&P 500 multiple of 20.80X. However, the stock is trading above its 12-month median P/E of 7.11X, suggesting potential overvaluation relative to its historical valuations.
Crocs’ Valuation Picture
Image Source: Zacks Investment Research
How to Play CROX Stock?Although Crocs continues to see attractive long-term opportunities in international markets, the business is facing mounting near-term challenges that could weigh on financial performance and investor sentiment. Weakening brand momentum and pressure on profitability reduce visibility into the pace of any meaningful recovery, while ongoing macroeconomic uncertainties create additional pressures. Given these risks, existing investors may consider reducing exposure, while prospective investors may prefer to remain on the sidelines until there is clearer evidence of sustained improvement in operating performance and a more favorable business environment. At present, CROX carries a Zacks Rank #4 (Sell).
You can see the complete list of today’s Zacks #1 Rank (Strong Buy) stocks here.
Gentex Corporation (GNTX) Q2 2026 Earnings Call July 24, 2026 9:30 AM EDT
Company Participants
Josh O'Berski - Vice President of Investor Relations
Steven Downing - President, CEO & Director
Kevin Nash - VP of Finance, CFO, Treasurer & Chief Accounting Officer
Neil Boehm - COO & CTO
Conference Call Participants
Joseph Spak - UBS Investment Bank, Research Division
Davis Baker - Robert W. Baird & Co. Incorporated, Research Division
James Picariello - BNP Paribas, Research Division
Josh Nichols - B. Riley Securities, Inc., Research Division
Mark Delaney - Goldman Sachs Group, Inc., Research Division
David Whiston - Morningstar Inc., Research Division
Rajat Gupta - JPMorgan Chase & Co, Research Division
Presentation
Operator
Good day, and thank you for standing by. Welcome to the Gentex Reports Second Quarter 2026 Financial Results Conference Call. [Operator Instructions] Please be advised that today's conference is being recorded. [Operator Instructions]
I would now like to hand the conference over to your speaker today, Josh O'Berski, Vice President of Investor Relations.
Josh O'Berski
Vice President of Investor Relations
Thank you. Good morning, and thank you for joining us today for our second quarter 2026 earnings conference call. I'm Josh O'Berski, Gentex's Vice President of Investor Relations. And with me today are Steve Downing, President and CEO; Neil Boehm, COO and CTO; and Kevin Nash, Vice President of Finance and CFO.
Please note that a replay of this conference call webcast, along with edited transcripts will be available following the call in the Investors section of our website at ir.gentex.com. Many of the statements made today during the call are forward-looking and reflect our current expectations. These statements involve a number of risks and uncertainties, both known and unknown, including those described in our press release issued this morning and in our annual report on Form 10-K for the year ended December 31, 2025, as well as general economic conditions.
Key Takeaways WM's Q2 revenues are expected to rise 4.4% y/y to $6.7 billion, with EPS up 3.7% to $1.99.Collection and disposal revenues are projected at $5.5 billion, nearly 82% of WM's quarterly sales.WM's renewable energy revenues are expected to rally 47%, helped by RNG, automation and new markets. WM (WM - Free Report) is scheduled to release second-quarter 2026 results on July 28, 2026, after market close.
WM surpassed the Zacks Consensus Estimate in two of the trailing four quarters and missed twice, the average earnings surprise being 0.6%.
WM’s Q2 ExpectationsThe Zacks Consensus Estimate for revenues is pegged at $6.7 billion, implying a 4.4% gain from the year-ago quarter’s actual. The top line is expected to have been driven by solid momentum across the total collection and disposal segment, contributing toward the majority of the top line. The remaining segments are anticipated to have contributed meaningfully to the top line as well.
The consensus estimate for total collection and disposal segment revenue is set at $5.5 billion, suggesting a 3.9% year-over-year rise. This segment is expected to account for nearly 82% of the top line in the second quarter of 2026. Revenue gains in this segment are likely to have stemmed from a focus on customer lifetime value, continuous operational improvement and network advantages.
For the recycling processing and sales segment, the consensus estimate for revenues is $397 million. This represents a 4.2% increase from the year-ago quarter’s actual. The Zacks Consensus Estimate for the WM renewable energy segment’s revenues is $169 million, suggesting a 47% year-over-year jump. Key drivers of recycling and renewable segments’ expansion likely include investments in renewable natural gas facilities, recycling automation and new market projects.
The consensus estimate for the WM healthcare solutions revenues hints at marginal year-over-year growth to $647 million. For the corporate and other segment, the Zacks Consensus Estimate is pinned at $7 million, suggesting no change from the year-ago quarter’s reported figure.
The consensus estimate for earnings per share is pegged at $1.99, hinting at a 3.7% increase from the year-ago quarter’s actual. Bottom-line growth is anticipated to have been driven by operational efficiencies and expanding margins across segments, capturing the growth momentum. Automation and AI-fueled technological support are expected to have been the prominent growth drivers as well.
What Our Model Predicts About WMOur proven model does not conclusively predict an earnings beat for WM this time around. The combination of a positive Earnings ESP and a Zacks Rank #1 (Strong Buy), 2 (Buy) or 3 (Hold) increases the odds of an earnings beat. But that is not the case here. You can uncover the best stocks to buy or sell before they are reported with our Earnings ESP Filter.
WM currently has an Earnings ESP of -1.31% and a Zacks Rank #3.
Stocks to ConsiderHere are a few stocks from the broader Business Services sector, which, according to our model, have the right combination of elements to beat on earnings this season.
Clean Harbors (CLH - Free Report) : The Zacks Consensus Estimate for the company’s second-quarter 2026 revenues is pinned at $1.6 billion, indicating 4.8% year-over-year growth. For earnings, the consensus estimate is pegged at $2.73 per share, implying a 15.7% jump from the year-ago quarter’s actual. The company beat the consensus estimate in three of the four quarters and missed once, with an average negative surprise of 0.02%.
CLH has an Earnings ESP of +3.82% and a Zacks Rank of 2 at present. You can see the complete list of today’s Zacks #1 Rank stocks here.
The company is scheduled to declare second-quarter 2026 results on July 29.
Veralto Corporation (VLTO - Free Report) : The Zacks Consensus Estimate for the company’s second-quarter 2026 revenues is $1.4 billion, suggesting a 4.9% year-over-year rise. For earnings, the consensus estimate is kept at a dollar per share, gaining 7.5% from the year-ago quarter’s actual. The company beat the consensus estimate in the trailing four quarters, with an average surprise of 4.9%.
VLTO has an Earnings ESP of +0.77% and a Zacks Rank of 3 at present. The company is scheduled to declare second-quarter 2026 results on July 28.
Key Takeaways Xylem is expected to post higher Q2 revenues and earnings, led by infrastructure and water solution demand.XYL may benefit from smart metering demand, backlog execution and contributions from the Vacom acquisition.Xylem faces margin pressure from higher material, labor, freight and strategic investment costs. Xylem Inc. (XYL - Free Report) is scheduled to release second-quarter 2026 results on July 28, before market open.
The Zacks Consensus Estimate for XYL’s second-quarter revenues is pegged at $2.33 billion, indicating growth of 1.2% from the prior-year quarter’s number. The consensus mark for earnings is pinned at $1.34 per share, which has been stable in the past 60 days. The figure indicates an increase of 6.4% from the year-ago quarter’s figure.
The company’s earnings surpassed the Zacks Consensus Estimate thrice in the trailing four quarters and matched the mark in one, the average surprise being 5.9%.
Let’s see how things have shaped up for Xylem this earnings season.
Factors Likely to Have Shaped XYL’s Quarterly PerformanceStrength in the transport application business, aided by increased infrastructure projects in the United States, is likely to have supported the Water Infrastructure segment’s performance. The Zacks Consensus Estimate for the Water Infrastructure segment’s revenues is pegged at $664 million, indicating 2.2% growth from the year-ago figure.
An increase in demand for advanced metering infrastructure solutions, like smart and energy metering, and strong backlog execution are likely to have augmented the performance of the Measurement & Control Solutions (M&CS) segment. The Zacks Consensus Estimate for the M&CS segment’s revenues is pinned at $538 million, almost in line with the year-ago quarter’s figure.
Strength in the Applied Water segment, supported by higher demand for commercial building solutions applications, including pumps, valves and dispensing equipment, is likely to augment the segment’s results. The Zacks Consensus Estimate for the Applied Water segment’s revenues is pegged at $492 million, indicating 1.9% growth from the year-ago figure.
Recovery in Xylem’s dewatering applications business across utility and power end markets is likely to augment the Water Solutions and Services segment’s results. The Zacks Consensus Estimate for the Water Solutions and Services segment’s revenues is pegged at $636 million, indicating 1.3% growth year over year.
The company’s acquisition of Vacom Systems (in April 2025), a wastewater treatment company, enhanced its capabilities in providing sustainable water solutions. This buyout is expected to bolster the company’s top-line results in the to-be-reported quarter.
However, XYL’s bottom line is likely to have reflected the impact of high raw material costs, labor, freight and overhead costs in the second quarter. Also, increased spending on strategic investments is expected to have hurt its margins.
Earnings WhisperOur proven model does not conclusively predict an earnings beat for Xylem this time around. The combination of a positive Earnings ESP and a Zacks Rank #1 (Strong Buy), 2 (Buy) or 3 (Hold) increases the odds of an earnings beat, which is not the case here, as elaborated below.
Earnings ESP: Xylem has an Earnings ESP of -0.34%. You can uncover the best stocks before they’re reported with our Earnings ESP Filter.
Zacks Rank: XYL presently carries a Zacks Rank of 3. You can see the complete list of today’s Zacks #1 Rank stocks here.
Stocks to ConsiderHere are some companies, which according to our model, have the right combination of elements to beat on earnings in this reporting cycle.
Crane Company (CR - Free Report) has an Earnings ESP of +4.73% and a Zacks Rank of 2 at present. The company is scheduled to release second-quarter 2026 results on July 28.
Crane’s earnings surpassed the Zacks Consensus Estimate in each of the preceding four quarters, the average surprise being 11.3%.
Ingersoll Rand Inc. (IR - Free Report) has an Earnings ESP of +0.61% and a Zacks Rank of 3 at present. The company is slated to release second-quarter 2026 results on July 30.
Ingersoll Rand’s earnings surpassed the Zacks Consensus Estimate in two of the trailing four quarters while matching the mark in two, the average surprise being 2.4%.
Illinois Tool Works Inc. (ITW - Free Report) has an Earnings ESP of +0.31% and a Zacks Rank of 3 at present. The company is slated to release second-quarter 2026 results on July 28.
Illinois Tool’s earnings surpassed the Zacks Consensus Estimate in each of the trailing four quarters, the average surprise being 2.8%.
Company backs the Barr-Craig framework and the administration's call to fix the federal hemp definition before the November deadline
, /PRNewswire/ -- cbdMD, Inc. (NYSE American: YCBD), a leader in hemp-derived wellness, today announced its support for the bipartisan Lawful Hemp Protection Act, introduced July 21 by Rep. Andy Barr (R-KY) and Rep. Angie Craig (D-MN). The legislation would establish a long-term federal regulatory framework for hemp-derived products while preserving consumer access to lawful products. The Company also expressed support for the Administration's call to address the federal hemp definition through pending budget legislation.
The legislation comes at a pivotal time for the U.S. hemp industry. Under Section 781 of the Fiscal Year 2026 appropriations law, the federal definition of hemp is scheduled to narrow on November 12, 2026. Without congressional action, many lawful full-spectrum CBD and hemp wellness products could be removed from the marketplace. The Lawful Hemp Protection Act would repeal that provision and replace it with a durable, science-based framework.
The bipartisan sponsorship reflects a growing consensus that responsible regulation, rather than prohibition, is the appropriate path forward for the hemp industry. The bill would establish FDA oversight for hemp-derived products, with mandatory third-party testing, transparent labeling, a 21-and-over age requirement, and domestic sourcing, while targeting the synthetic intoxicants that have drawn scrutiny to the category.
Specifically, cbdMD supports a federal framework that:
Protects access to responsibly manufactured full-spectrum CBD Requires independent testing and accurate labeling Establishes clear manufacturing and marketing standards, including limits on youth-focused marketing Prevents youth access through a 21-and-over requirement Restricts synthetic and artificially modified cannabinoids Preserves lawful interstate commerce for compliant products cbdMD also welcomed the Office of Management and Budget's recent call for Congress to update the hemp definition through the funding process, which the company believes could provide relief before the November deadline if enacted.
As one of the nation's longest-standing hemp-derived CBD companies, cbdMD believes a consistent federal regulatory framework would significantly benefit consumers and responsible businesses alike by improving consumer confidence, strengthening safety standards, and providing greater certainty for manufacturers and retailers.
"Reps. Barr and Craig have demonstrated bipartisan leadership by advancing a practical regulatory framework for hemp-derived products," said Ronan Kennedy, Chief Executive Officer of cbdMD. "Responsible companies have long supported clear federal standards that protect consumers, promote product quality, and distinguish compliant hemp products from illicit synthetic intoxicants. We encourage Congress to act before the November implementation deadline."
About cbdMD, Inc.
cbdMD, Inc. (NYSE American: YCBD) is a Charlotte, North Carolina-based hemp-derived wellness company committed to safe, high-quality, science-backed products. Its family of brands includes cbdMD, cbdMD Science, Bluebird Botanicals, Paw CBD, Oasis, and ATRx Labs. For more information, visit cbdMD.com.
Forward-Looking Statements
This press release contains forward-looking statements within the meaning of the federal securities laws. Statements regarding pending legislation, regulatory developments, and their potential impact on the company are based on current expectations and are subject to risks and uncertainties, including the outcome of the legislative and regulatory processes described above and risks disclosed in the Company's filings with the U.S. Securities and Exchange Commission, including its most recent Annual Report on Form 10-K and subsequent Quarterly Reports on Form 10-Q. Actual results may differ materially. The company undertakes no obligation to update any forward-looking statement except as required by law.
Contacts
cbdMD, Inc.
Ronan Kennedy
Chief Executive Officer and Chief Financial Officer
[email protected]
(704) 445-3064
Capital One (COF) is rated Strong Buy with a $260 price target, 26% above current levels, driven by technology-led competitive advantages. COF's cloud-native infrastructure, AI leadership, and ownership of the Discover network position it for payments-grade returns on tangible equity. Despite low-20s% normalized ROTCE post-integration, COF trades at ~9.4x forward earnings and ~1.9x tangible book, a deep discount to peers like Amex.
Founder's ClubSwingTraderLeaderboardMarketSurgeeIBDIBD DigitalIBD LiveCustomer Center
My Stock Lists
Email Preferences
Help & Support
Sign Out
Search stocks or keywords
Sections
My IBD
MARKET TREND
STOCK LISTS
STOCK RESEARCH
NEWSECONOMY
VIDEOS & PODCASTS
HOW TO INVESTEDUCATIONAL RESOURCESStoreMy Products
Founder's ClubSwingTraderLeaderboardMarketSurgeeIBDIBD DigitalIBD Live
Recently Searched
United Rentals, These Other Top Stocks Hit Record Highs While Rest Of Market Snoozes
Nasdaq Dives As Red Sea Attacks Propel Oil Prices; Alphabet, Tesla Plunge Post-Earnings
Stocks Slammed As Oil, Yields Surge Again; Applied Materials, Viking, United Rentals In Focus Stocks from four different sectors have been clinging to new highs amid the tech sector sell-off during June and July. One of them is finance name KeyCorp (KEY), which broke out of a cup-with-handle base at a pivot of 22.55 in June before making it to a four-year high last week. KeyCorp provides deposit, lending, cash management, and investment services…
Key Takeaways Generac's Q2 sales and earnings estimates imply year-over-year growth of 11% and 18.2%.Data center demand and hyperscale opportunities are expected to power C&I growth in the quarter.Q2 adjusted EBITDA margin is expected near 18%, with faster improvement projected later in 2026. Generac Holdings Inc. (GNRC - Free Report) will report second-quarter 2026 results on July 29, before the market opens.
The Zacks Consensus Estimate for revenues is pinned at $1.18 billion, up 11% from the prior-year reported number. The consensus estimate for earnings is $1.95 per share, up 18.2% year over year. The estimate has remained unchanged in the past 60 days.
GNRC’s earnings beat the Zacks Consensus Estimate in two of the trailing four quarters and missed twice, delivering an average surprise of 7.4%.
Price Performance
Image Source: Zacks Investment Research
In the past year, shares of the company have gained 34.1% compared with the Zacks Manufacturing-General Industrial industry’s growth of 3.5%.
Factors at Play Ahead of GNRC’s Q2 ResultsGenerac entered second-quarter 2026 against a backdrop of increasing momentum in its Commercial & Industrial (C&I) segment, driven by robust data center demand, while Residential trends remain more back-half weighted.
Management guided to second-quarter consolidated net sales growth of approximately 9% to 10% year over year, with growth entirely driven by the C&I segment. On the last earnings call, the company highlighted that it was in the final stages of vendor approval with two hyperscale customers. It has also been witnessing backlog expansion for these products with both current and new customers.
Generac’s data center backlog reached more than $700 million at the first quarter-end, representing a roughly $300 million increase since mid-February and providing visibility into 2027 deliveries. Importantly, this number excludes a nonbinding notice to proceed for $600 million in hyperscale data center deliveries expected in 2027, indicating substantial upside potential as the pipeline converts into firm orders. The company has been focused on capacity expansion for large megawatt generators to support accelerating demand.
Within the Residential segment, meaningful growth is skewed toward the second half of 2026, driven by home standby generator, supported by easier comparisons.
Within residential energy technology, ecobee has been emerging as a strategic asset, with more than 5 million connected homes and increased energy services and subscription sales. With the integration of PWRcell 2, PowerMicro microinverter and next-gen standby generators with ecobee, Generac aims to create a differentiated residential energy ecosystem.
Generac expects second-quarter adjusted EBITDA margins to be 18%, representing modest year-over-year expansion. Margin improvement is expected to accelerate in the back half of the year, driven by operating leverage on higher volumes and contributions from the Enercon acquisition.
Nonetheless, volatile macroeconomic conditions, including tariff troubles, stiff competition and increasing operating costs remain additional concerns for Generac.
Heavy reliance on the residential business exposes Generac to weather-driven volatility. Further, data center market expansion brings its own set of concerns. With increasing reliance on this end market, Generac is exposed to cyclical capital spending cycles in AI and data centers. Any delays in manufacturing capacity expansion could also weigh on growth targets.
Also, Residential energy growth in 2025 was largely driven by Puerto Rico’s energy grant-related program. However, with the completion of the program, energy storage systems declined in the first quarter. GNRC is also recalibrating its investments and expects the solar and storage market to contract in 2026 due to reduced U.S. federal incentives.
Key HighlightsOn June 15, 2026, Generac announced an expansion of its packaging capacity for large-megawatt generators through the acquisition of a new facility in Belvidere, IL.
On June 2, 2026, Generac announced a supply agreement with a major hyperscale data center operator to provide backup power generators for its data center infrastructure following a comprehensive qualification and audit process.
What Does Our Model Unveil for GNRC?Our proven model does not predict an earnings beat for Generac this time around. The combination of a positive Earnings ESP and a Zacks Rank #1 (Strong Buy), 2 (Buy), or 3 (Hold) increases the odds of an earnings beat. This not the case here.
Generac has an Earnings ESP of 0.00% and a Zacks Rank #2 at present. You can uncover the best stocks to buy or sell before they’re reported with our Earnings ESP Filter.
Stocks to ConsiderHere are a few stocks that you may want to consider, as our model shows that these have the right combination of elements to post an earnings beat this season.
Celestica (CLS - Free Report) currently has an Earnings ESP of +1.86% and a Zacks Rank #2. You can see the complete list of today’s Zacks #1 Rank stocks here.
Celestica is scheduled to report quarterly earnings on July 27. The Zacks Consensus Estimate for CLS’ to-be-reported quarter’s earnings and revenues stands at $2.29 per share and $4.35 billion, respectively. Shares of Celestica have gained 96.7% in the past year.
Seagate Technology Holdings plc (STX - Free Report) has an Earnings ESP of +1.75% and a Zacks Rank #1 at present. STX is scheduled to report quarterly figures on July 28. The Zacks Consensus Estimate for Seagate Technology’s to-be-reported quarter’s earnings and revenues is pinned at $5.10 per share and $3.49 billion, respectively. Shares of Seagate Technology are up 505.3% in the past year.
Teradyne (TER - Free Report) has an Earnings ESP of +0.59% and a Zacks Rank #2 at present. The company is scheduled to report quarterly figures on July 28. The Zacks Consensus Estimate for Teradyne’s to-be-reported quarter’s earnings and revenues is pinned at $2.04 per share and $1.22 billion, respectively. Shares of Teradyne are up 314.6% in the past year.
Key Takeaways BWXT combines government nuclear contracts with expanding commercial nuclear operations and acquisitions.BWX Technologies trades at 4.06X forward sales versus XE at 11.34X forward sales.BWXT shares fell 20.9% in three months versus a 45.5% decline for XE shares. As investor interest in nuclear energy continues to grow, both X-Energy (XE - Free Report) and BWX Technologies (BWXT - Free Report) have emerged as attractive ways to gain exposure to the sector. While both companies operate within the U.S. nuclear industry, they represent two very different investment opportunities. While BWX Technologies is a mature, profitable supplier of nuclear components and services to the U.S. government with decades of industry experience, X-Energy is an emerging advanced reactor developer focused on commercializing next-generation nuclear technology.
The global nuclear industry is entering a new growth cycle as governments seek reliable, carbon-free sources of electricity to complement renewable energy and strengthen energy security. Rising electricity demand driven by artificial intelligence, data centers, electrification, and industrial decarbonization is increasing the need for dependable baseload power, while geopolitical concerns have prompted many countries to reduce reliance on imported fossil fuels. As a result, governments are extending the operating lives of existing nuclear plants, restarting previously retired reactors, and investing in next-generation technologies such as small modular reactors (SMRs) and advanced reactors.
Let us compare the stocks' fundamentals to determine which one is a better investment option at present.
Factors Acting in Favor of XE StockX-Energy is focused on the future of commercial nuclear power. The company is developing the Xe-100, a Generation IV high-temperature gas-cooled SMR designed to provide carbon-free electricity, industrial heat, and hydrogen production. Unlike traditional large nuclear plants, the Xe-100 is modular, scalable, and intended to be easier and less expensive to deploy. XE is also developing TRISO-X, a business dedicated to manufacturing TRISO fuel, an advanced nuclear fuel known for its exceptional safety characteristics and high-temperature performance. The company expects fuel production to become a meaningful long-term revenue stream as advanced reactors are deployed globally.
As of March 31, 2026, the company had a project pipeline of 144 Xe-100 reactors, representing roughly 11.5 gigawatts electric (GWe) of potential capacity across the United States and the United Kingdom. This pipeline is anchored by major customers and partners including Dow, Amazon and Centrica, providing the company with a solid foundation for future reactor sales, fuel supply agreements and long-term service revenues.
Factors Acting in Favor of BWXT StockBWX Technologies has built its business around designing and manufacturing nuclear components, fuel, and reactor systems for the U.S. Navy, Department of Energy, NASA, and other government agencies. The company is the sole manufacturer of naval nuclear reactors for U.S. aircraft carriers and submarines, giving it a highly defensible competitive position supported by long-term government contracts and recurring revenues. In recent years, BWXT has also expanded its commercial nuclear operations by supplying components, fuel handling systems, and engineering services for existing nuclear power plants, while increasing its presence in medical isotopes and advanced reactor technologies. This diversified business model provides stable cash flows and relatively predictable earnings growth.
In April 2026, BWXT announced the acquisition of Precision Components Group, LLC. This marks BWXT’s first step in establishing a U.S. commercial nuclear component manufacturing footprint to support future new reactor builds and aftermarket.
How Does the Zacks Consensus Estimate Compare for XE & BWXT?The Zacks Consensus Estimate for X-Energy’s 2027 earnings per share (EPS) indicates growth of 15.09% year over year.
Image Source: Zacks Investment Research
The Zacks Consensus Estimate for BWX Technologies’ 2027 EPS implies growth of 13.74% year over year.
Image Source: Zacks Investment Research
Valuation for XE & BWXTXE shares trade at a forward 12-month price/sales (P/S F12M) of 11.34X compared with BWXT’s P/S F12M of 4.06X.
Image Source: Zacks Investment Research
XE & BWXT’s Price PerformanceIn the past three months, shares of X-Energy and BWX Technologies’ have declined 45.5% and 20.9%, respectively.
Image Source: Zacks Investment Research
XE or BWXT: Which Is a Better Choice Now?X-Energy is developing advanced SMR technology for commercial nuclear power, with a focus on delivering carbon-free electricity, industrial heat, and hydrogen production through scalable reactor designs. XE is also building an advanced nuclear fuel business, supported by a growing pipeline of projects and partnerships that position it for long-term reactor, fuel, and service revenue opportunities.
BWX Technologies specializes in nuclear components, fuel, and reactor systems for U.S. government agencies, supported by long-term contracts that provide stable and recurring revenues. BWXT is also expanding its commercial nuclear business through advanced reactor technologies, nuclear services, and strategic acquisitions that strengthen its position in the growing commercial market.
Our choice at the moment is BWX Technologies, given its better price performance and more attractive valuation than X-Energy. BWXT carries a Zacks Rank #3 (Hold) and XE has a Zacks Rank #4 (Sell) at present. You can see the complete list of today’s Zacks #1 Rank (Strong Buy) stocks here.
WSFS Financial NASDAQ: WSFS reported second-quarter 2026 core earnings per share of $1.66, core return on assets of 1.55% and core return on tangible common equity of 20.2%, with management citing growth in fee businesses, deposits and selected lending categories.
Chief Financial Officer David Burg said core net income rose 19% from a year earlier, while core pre-provision net revenue increased 10%. Core EPS grew 31% year over year, and tangible book value per share increased 13%.
Get WSFS Financial alerts:
Core results excluded a $1.8 million reduction in net income, or $0.03 per share, primarily associated with the write-down of an equity investment, as well as the previously disclosed gain on the sale of the company’s credit-card portfolio.
Margin Expands as Deposit Costs Decline Net interest margin expanded 4 basis points from the first quarter to 3.87%. Burg attributed the increase to a 4-basis-point decline in client deposit costs and higher investment-security yields. The company’s interest-bearing deposit beta remained at 46%.
Management updated its full-year 2026 outlook based on an assumption that the federal funds rate will not change during the remainder of the year. WSFS now expects net interest margin of approximately 3.85% for the year.
During the question-and-answer session, Burg said the company expects to manage its margin despite a more competitive deposit environment. WSFS has allowed some higher-cost deposits to run off during the first half because of its liquidity position, he said, but may need to raise rates in certain areas to remain competitive and support client growth.
“We want to make sure that we remain competitive,” Burg said, noting that deposit competition had increased during the prior six months. “There could be some upward pressure on deposit costs.”
Fee Revenue and Institutional Services Growth Core fee revenue, which represented nearly one-third of total revenue, increased 2% from the first quarter and 5% from a year earlier. Wealth and trust revenue grew 17% year over year.
Within Institutional Services, corporate trust revenue rose 28% year over year and global capital markets revenue increased 58%, according to Burg. The company said it continued to win mandates and gain market share in those businesses.
For the first half of 2026, WSFS ranked as the third-most-active asset-backed securities and mortgage-backed securities trustee by deal count, increasing its market share to 14% from 11.7% in 2025, Burg said. Bryn Mawr Trust Company of Delaware, the company’s personal trust operation, grew 20% year over year as new accounts increased.
Cash Connect fees declined from a year earlier because of interest-rate cuts and lower volumes. However, the business delivered a 15% profit margin for the second consecutive quarter.
Burg told analysts that the ABS and MBS market has continued to expand, with industry growth of roughly 20% to 30%, while WSFS has also increased its share. He said the company’s ability to move quickly and provide service has helped it compete with larger players, though he cautioned against extrapolating the current pace of market growth.
Deposits, Loans and Asset Quality Client deposits increased 3% sequentially and 11% year over year, led by Institutional Services and commercial banking. Non-interest-bearing deposits climbed 10% from the first quarter and accounted for 37% of total client deposits, compared with 31% a year earlier. Average deposits rose 3% sequentially and 8% year over year.
Burg said approximately 80% of the quarter’s non-interest-bearing deposit growth came from Institutional Services, split between corporate trust and global capital markets, with the remaining 20% coming from commercial banking. He said the company historically has operated with non-interest-bearing deposits in the low 30% range and would view a low-to-mid-30% level as a favorable sustainable range.
Gross loans increased 1% from the prior quarter, equivalent to a 5% annualized pace. Commercial and industrial loans rose 2% sequentially, or 8% annualized. Residential mortgages and WSFS home-equity loans increased 10% sequentially and 23% year over year.
Chairman, President and CEO Rodger Levenson said client sentiment appeared constructive despite cost pressures and uncertainty tied to geopolitical developments and energy volatility. He said businesses were continuing to invest in a relatively stable economic environment, supporting the company’s commercial loan pipeline.
Management said home-lending growth may moderate after a strong spring selling season. Burg said the residential pipeline had declined somewhat as the seasonal market slowed and rates rose.
Asset-quality measures improved during the quarter. Problem assets fell 6% sequentially and 31% year over year, aided by commercial payoffs. Delinquencies declined 5% from the first quarter and nearly 40% from a year earlier, while nonperforming assets fell 8% sequentially and nearly 25% year over year.
Net charge-offs were $7.1 million, or 21 basis points of average loans. Excluding the prior quarter’s loan recovery, net charge-offs declined $5.1 million sequentially because of lower commercial charge-offs. Management said office properties remain a challenging area, but it did not identify a broader portfolio trend or asset-class concern.
Capital Returns and Updated Outlook WSFS returned $77 million of capital during the second quarter, including $66 million of share repurchases. Year to date, the company repurchased more than 4% of its outstanding shares and returned approximately 100% of net income to shareholders.
Burg said the company’s first priority remains investing in the business at attractive returns. Management said it would consider acquisitions that are additive to its strategy, including potential opportunities in fee businesses and wealth management, but Levenson said the bar for bank acquisitions would be high given the company’s organic opportunities in its existing markets.
Full-year return on assets outlook was raised to 1.50%, with potential for modest upside. Deposit growth outlook was raised to the high-single-digit range. Fee revenue growth, excluding Cash Connect, is expected in the mid-to-high-single-digit range. Expected net charge-offs were lowered to 15 to 25 basis points of average loans for the year. The company maintained its efficiency outlook in the high-50% range. Burg said expenses could remain around current levels or be somewhat lower, though variable compensation, transaction-related costs, health-care expenses and fraud-related costs could create quarterly variability. He said the company is pursuing cost initiatives involving vendor spending, real estate optimization and exits from businesses that are not central to its strategy.
About WSFS Financial (NASDAQ:WSFS)WSFS Financial Corporation is the bank holding company for WSFS Bank, a regional financial institution headquartered in Wilmington, Delaware. The company traces its roots to the Safe Deposit & Trust Company, founded in 1832, and formally organized as WSFS Financial in the mid-1980s. Over its long history, WSFS has grown through a combination of organic expansion and selective acquisitions to serve a broad base of individual, commercial and institutional clients.
WSFS Bank offers a full suite of banking and financial services, including retail and commercial deposit accounts, commercial and industrial lending, real estate financing, and treasury management solutions.
This instant news alert was generated by narrative science technology and financial data from MarketBeat in order to provide readers with the fastest reporting and unbiased coverage. Please send any questions or comments about this story to [email protected].
Should You Invest $1,000 in WSFS Financial Right Now?Before you consider WSFS Financial, you'll want to hear this.
MarketBeat keeps track of Wall Street's top-rated and best performing research analysts and the stocks they recommend to their clients on a daily basis. MarketBeat has identified the five stocks that top analysts are quietly whispering to their clients to buy now before the broader market catches on... and WSFS Financial wasn't on the list.
While WSFS Financial currently has a Moderate Buy rating among analysts, top-rated analysts believe these five stocks are better buys.
View The Five Stocks Here
Enter your email address and we’ll send you MarketBeat’s list of ten stocks set to soar in Summer 2026, despite the threat of tariffs and what's happening in Iran. These ten stocks are incredibly resilient and are likely to thrive in any economic environment.
Momentum investing is all about the idea of following a stock's recent trend, which can be in either direction. In the "long context," investors will essentially be "buying high, but hoping to sell even higher." And for investors following this methodology, taking advantage of trends in a stock's price is key; once a stock establishes a course, it is more than likely to continue moving in that direction. The goal is that once a stock heads down a fixed path, it will lead to timely and profitable trades.
While many investors like to look for momentum in stocks, this can be very tough to define. There is a lot of debate surrounding which metrics are the best to focus on and which are poor quality indicators of future performance. The Zacks Momentum Style Score, part of the Zacks Style Scores, helps address this issue for us.
Below, we take a look at First BanCorp (FBP - Free Report) , a company that currently holds a Momentum Style Score of A. We also talk about price change and earnings estimate revisions, two of the main aspects of the Momentum Style Score.
It's also important to note that Style Scores work as a complement to the Zacks Rank, our stock rating system that has an impressive track record of outperformance. First BanCorp currently has a Zacks Rank of #1 (Strong Buy). Our research shows that stocks rated Zacks Rank #1 (Strong Buy) and #2 (Buy) and Style Scores of "A or B" outperform the market over the following one-month period.
You can see the current list of Zacks #1 Rank Stocks here >>>
Set to Beat the Market? In order to see if FBP is a promising momentum pick, let's examine some Momentum Style elements to see if this holding company for FirstBank Puerto Rico holds up.
A good momentum benchmark for a stock is to look at its short-term price activity, as this can reflect both current interest and if buyers or sellers currently have the upper hand. It's also helpful to compare a security to its industry; this can show investors the best companies in a particular area.
For FBP, shares are up 2.85% over the past week while the Zacks Banks - Foreign industry is flat over the same time period. Shares are looking quite well from a longer time frame too, as the monthly price change of 8.7% compares favorably with the industry's 3.18% performance as well.
Considering longer term price metrics, like performance over the last three months or year, can be advantageous as well. Shares of First BanCorp have increased 18.82% over the past quarter, and have gained 37.58% in the last year. In comparison, the S&P 500 has only moved 4.48% and 17.65%, respectively.
Investors should also take note of FBP's average 20-day trading volume. Volume is a useful item in many ways, and the 20-day average establishes a good price-to-volume baseline; a rising stock with above average volume is generally a bullish sign, whereas a declining stock on above average volume is typically bearish. Right now FBP is averaging 1,513,627 shares for the last 20 days..
Earnings OutlookThe Zacks Momentum Style Score encompasses many things, including estimate revisions and a stock's price movement. Investors should note that earnings estimates are also significant to the Zacks Rank, and a nice path here can be promising. We have recently been noticing this with FBP.
Over the past two months, 4 earnings estimates moved higher compared to none lower for the full year. These revisions helped boost FBP's consensus estimate, increasing from $2.25 to $2.36 in the past 60 days. Looking at the next fiscal year, 4 estimates have moved upwards while there have been no downward revisions in the same time period.
Bottom LineGiven these factors, it shouldn't be surprising that FBP is a #1 (Strong Buy) stock and boasts a Momentum Score of A. If you're looking for a fresh pick that's set to soar in the near-term, make sure to keep First BanCorp on your short list.
New York, New York--(Newsfile Corp. - July 24, 2026) - WHY: Rosen Law Firm, a global investor rights law firm, reminds purchasers of securities of Insulet Corporation (NASDAQ: PODD) between February 21, 2025 and May 26, 2026, inclusive (the "Class Period"), of the important August 31, 2026 lead plaintiff deadline.
SO WHAT: If you purchased Insulet securities during the Class Period you may be entitled to compensation without payment of any out of pocket fees or costs through a contingency fee arrangement.
WHAT TO DO NEXT: To join the Insulet class action, go to https://rosenlegal.com/cases/insulet-corporation/join or call Phillip Kim, Esq. toll-free at 866-767-3653 or email [email protected] for information on the class action. A class action lawsuit has already been filed. If you wish to serve as lead plaintiff, you must move the Court no later than August 31, 2026. A lead plaintiff is a representative party acting on behalf of other class members in directing the litigation.
WHY ROSEN LAW: We encourage investors to select qualified counsel with a track record of success in leadership roles. Often, firms issuing notices do not have comparable experience, resources, or any meaningful peer recognition. Many of these firms do not actually handle securities class actions, but are merely middlemen that refer clients or partner with law firms that actually litigate the cases. Be wise in selecting counsel. The Rosen Law Firm represents investors throughout the globe, concentrating its practice in securities class actions and shareholder derivative litigation. Rosen Law Firm has achieved the largest ever securities class action settlement against a Chinese Company. Rosen Law Firm was Ranked No. 1 by ISS Securities Class Action Services for number of securities class action settlements in 2017. The firm has been ranked in the top 4 each year since 2013 and has recovered billions of dollars for investors. In 2019 alone the firm secured over $438 million for investors. In 2020, founding partner Laurence Rosen was named by law360 as a Titan of Plaintiffs' Bar. Many of the firm's attorneys have been recognized by Lawdragon and Super Lawyers.
DETAILS OF THE CASE: According to the lawsuit, defendants made false and/or misleading statements and/or failed to disclose that: (1) Insulet's manufacturing controls and procedures were defective; (2) the foregoing created a foreseeable heightened risk that one or more Insulet products would be found to be in violation of applicable safety regulations and/or pose a risk of injury; and (3) as a result, defendants' public statements were materially false and misleading at all relevant times. When the true details entered the market, the lawsuit claims that investors suffered damages.
To join the Insulet class action, go to https://rosenlegal.com/cases/insulet-corporation/join or call Phillip Kim, Esq. toll-free at 866-767-3653 or email [email protected] for information on the class action.
No Class Has Been Certified. Until a class is certified, you are not represented by counsel unless you retain one. You may select counsel of your choice. You may also remain an absent class member and do nothing at this point. An investor's ability to share in any potential future recovery is not dependent upon serving as lead plaintiff.
Follow us for updates on LinkedIn: https://www.linkedin.com/company/the-rosen-law-firm, on Twitter: https://twitter.com/rosen_firm or on Facebook: https://www.facebook.com/rosenlawfirm/.
Attorney Advertising. Prior results do not guarantee a similar outcome.
-------------------------------
To view the source version of this press release, please visit https://www.newsfilecorp.com/release/306488
Source: The Rosen Law Firm PA
Ready to Announce with Confidence? Send us a message and a member of our TMX Newsfile team will contact you to discuss your needs.
Cabot (CBT - Free Report) could be a solid choice for investors given its recent upgrade to a Zacks Rank #2 (Buy). An upward trend in earnings estimates -- one of the most powerful forces impacting stock prices -- has triggered this rating change.
The Zacks rating relies solely on a company's changing earnings picture. It tracks EPS estimates for the current and following years from the sell-side analysts covering the stock through a consensus measure -- the Zacks Consensus Estimate.
Since a changing earnings picture is a powerful factor influencing near-term stock price movements, the Zacks rating system is very useful for individual investors. They may find it difficult to make decisions based on rating upgrades by Wall Street analysts, as these are mostly driven by subjective factors that are hard to see and measure in real time.
Therefore, the Zacks rating upgrade for Cabot basically reflects positivity about its earnings outlook that could translate into buying pressure and an increase in its stock price.
Most Powerful Force Impacting Stock PricesThe change in a company's future earnings potential, as reflected in earnings estimate revisions, and the near-term price movement of its stock are proven to be strongly correlated. The influence of institutional investors has a partial contribution to this relationship, as these big professionals use earnings and earnings estimates to calculate the fair value of a company's shares. An increase or decrease in earnings estimates in their valuation models simply results in higher or lower fair value for a stock, and institutional investors typically buy or sell it. Their bulk investment action then leads to price movement for the stock.
For Cabot, rising earnings estimates and the consequent rating upgrade fundamentally mean an improvement in the company's underlying business. And investors' appreciation of this improving business trend should push the stock higher.
Harnessing the Power of Earnings Estimate RevisionsEmpirical research shows a strong correlation between trends in earnings estimate revisions and near-term stock movements, so it could be truly rewarding if such revisions are tracked for making an investment decision. Here is where the tried-and-tested Zacks Rank stock-rating system plays an important role, as it effectively harnesses the power of earnings estimate revisions.
The Zacks Rank stock-rating system, which uses four factors related to earnings estimates to classify stocks into five groups, ranging from Zacks Rank #1 (Strong Buy) to Zacks Rank #5 (Strong Sell), has an impressive externally-audited track record, with Zacks Rank #1 stocks generating an average annual return of +25% since 1988. You can see the complete list of today's Zacks #1 Rank (Strong Buy) stocks here >>>> .
Earnings Estimate Revisions for CabotThis chemical company is expected to earn $6.35 per share for the fiscal year ending September 2026, which represents no year-over-year change.
Analysts have been steadily raising their estimates for Cabot. Over the past three months, the Zacks Consensus Estimate for the company has increased 1.3%.
Bottom LineUnlike the overly optimistic Wall Street analysts whose rating systems tend to be weighted toward favorable recommendations, the Zacks rating system maintains an equal proportion of "buy" and "sell" ratings for its entire universe of more than 4,000 stocks at any point in time. Irrespective of market conditions, only the top 5% of the Zacks-covered stocks get a "Strong Buy" rating and the next 15% get a "Buy" rating. So, the placement of a stock in the top 20% of the Zacks-covered stocks indicates its superior earnings estimate revision feature, making it a solid candidate for producing market-beating returns in the near term.
You can learn more about the Zacks Rank here >>>
The upgrade of Cabot to a Zacks Rank #2 positions it in the top 20% of the Zacks-covered stocks in terms of estimate revisions, implying that the stock might move higher in the near term.
The company reported adjusted earnings of $7.59, up from $6.84 a year ago, surpassing the Wall Street estimates of $7.02.
Adjusted EBITDA reached $4.027 billion, compared to $3.849 billion a year ago.
Admissions Growth And Medicaid Payments Support ResultsThe company also experienced positive factors including increased benefit from Medicaid Supplemental Payment Programs, growth in admissions, equivalent admissions and ER visits, and improved expense results.
Same facility admissions increased 2.5% and same facility equivalent admissions increased 2.7%. Same facility emergency room visits increased 3.6%.
Same facility inpatient surgeries declined 2.3%, and outpatient surgeries declined 3.4% in the quarter. Same facility revenue per equivalent admission increased 6.4%.
Surgical Volume And Payer Mix Weigh On PerformanceAs announced earlier, during the second quarter, the company experienced a payer mix shift driven by an increase in uninsured volume, primarily due to patients who lost coverage on the health insurance exchanges.
The company estimates this payer mix shift had an unfavorable impact on income before income taxes of approximately $400 million during the second quarter.
The amount includes an increase of approximately $75 million related to the company’s previous estimate of the first quarter health insurance exchange impact.
In addition, to a lesser degree, HCA Healthcare experienced a service mix shift primarily related to a decline in surgical volume.
HCA Reaffirms Full-Year 2026 OutlookHCA Healthcare reaffirmed fiscal 2026 earnings guidance of $28.70-$30.50 per share compared to the consensus of $29.70.
The company expects 2026 sales of $77 billion-$79.50 billion versus the consensus of $78.457 billion.
HCA Stock Price Activity: HCA Healthcare shares were up 3.62% at $390.12 at the time of publication on Friday, according to Benzinga Pro data.
Photo: Shutterstock
Market News and Data brought to you by Benzinga APIs
Healthcare Added 35,200 Jobs—3 Stocks Positioned to BenefitHCA Healthcare NYSE: HCA said its second-quarter performance reflected solid demand in several service lines and 11% growth in diluted earnings per share, but the company faced increased financial pressure as patients losing health insurance exchange coverage shifted largely into the uninsured population.
Chief Executive Officer Sam Hazen said the expiration of enhanced premium tax credits at the end of 2025 led more patients to lose exchange coverage than the company had anticipated. While HCA expected some individuals to move to other coverage options, Hazen said patients instead migrated “almost one for one” to uninsured status while continuing to require hospital care.
Get HCA Healthcare alerts:
The Aging of America Could Make HCA Healthcare a Long-Term Winner“The effects, as expected, were that many people became uninsured and still needed emergency care from hospitals,” Hazen said. He added that the impact in the first half of 2026 was greater than the company’s original estimates.
Payer Mix Shift Drives Updated Outlook Same-facility equivalent admissions among patients covered through health insurance exchanges declined 15% in the second quarter and year to date, according to Chief Financial Officer Mike Marks. Equivalent admissions among insured patients excluding exchange plans increased 3.2% in the second quarter, while total uninsured equivalent admissions rose 15%.
This ETF Is Proof That the Healthcare Rebound Is RealMarks said the exchange-related payer mix shift created an approximately $400 million unfavorable impact on adjusted EBITDA in the second quarter. That figure included about $75 million tied to a higher estimate of the first-quarter exchange impact.
The company now expects the full-year adjusted EBITDA impact from health insurance exchange changes to range from negative $1 billion to negative $1.2 billion. Marks said the updated outlook reflects the company’s conclusion that nearly all patients losing exchange coverage are becoming uninsured, compared with its prior assumption that 80% to 85% would do so. HCA also said its original expectation that uninsured patients would use fewer healthcare services did not materialize.
Three divisions—Gulf Coast, North Florida and South Atlantic—accounted for about half of the companywide exchange-related impact. Hazen said exchange adjusted admissions in those divisions declined between 25% and 28% in the first half.
HCA revised its full-year 2026 guidance to:
Revenue of $77 billion to $79.5 billion. Adjusted EBITDA of $15.4 billion to $16.1 billion. Net income attributable to HCA Healthcare of $6.3 billion to $6.7 billion. Diluted earnings per share of $28.70 to $30.50. Marks said the revised outlook is more consistent with HCA’s long-term adjusted EBITDA growth target of 4% to 6%, following moderation from the company’s 2025 growth rate and its initial 2026 assumptions.
Medicaid Programs Offset Pressure in the Quarter The company recognized approximately $400 million of incremental net benefit from Medicaid supplemental payment programs during the second quarter. That included a $540 million incremental net benefit related to a recently approved Florida program covering the period from Oct. 1, 2024, through June 30, 2026, or 21 months.
The Florida benefit was partly offset by retroactive payments received in the second quarter of 2025. HCA’s annual guidance assumes a net Medicaid supplemental-payment benefit of $300 million to $500 million, but Marks said the outlook implies a $100 million to $300 million headwind in the second half because prior program approvals and retroactive payments are expected to exceed the incremental benefit from the Florida program.
Hazen described Medicaid supplemental programs as important to supporting access to care for Medicaid patients, particularly as hospitals provide more uncompensated care to uninsured patients.
Demand Growth Continues, Though Surgeries Decline Same-facility admissions increased 2.5% in the second quarter, while equivalent admissions rose 2.7%. Emergency room visits increased 3.6%, with cardiac procedures and rehabilitation volumes also contributing to demand.
However, inpatient surgeries declined 2.3% and outpatient surgeries fell 3.4%. Hazen attributed much of the decline to reduced demand for elective procedures, including patients previously covered through exchange plans. He also cited physician feedback regarding affordability pressures affecting patients and the effect of Medicare inpatient rule changes that have shifted some cases from inpatient to outpatient settings.
Emergency inpatient surgeries, which account for about two-thirds of HCA’s inpatient surgical cases, increased 2% year over year through the first six months. By contrast, elective inpatient surgeries were down 6% this year, compared with a 2% decline in the prior year.
Despite the surgical weakness, Hazen said the company remains encouraged by demand and continues to expect long-term demand growth of 2% to 3%, supported by population growth and market trends in its communities.
Capital Investment and Cost Initiatives HCA has approved more than $7 billion of capital spending expected to come online over the next three years. The investments include 1,000 to 1,200 additional inpatient beds, new hospitals in certain markets, and additional outpatient facilities.
Hazen said the company had approximately 42,000 beds currently in operation, up from roughly 37,000 at the end of 2018. Occupancy increased to 75% from 71% over that period. HCA also had 5% more outpatient sites of care in the second quarter than a year earlier and expects another 250 to 300 outpatient facilities in its capital or acquisition pipeline to open later this year or early next year.
The company spent $1.2 billion on capital expenditures during the quarter, repurchased $2.1 billion of shares and paid $171 million in dividends. Cash flow from operations was $2.3 billion, down 45% year over year, primarily because of the timing of Florida Medicaid supplemental-payment cash flows and the prior-year deferral of federal income tax payments.
HCA maintained its planned 2026 capital expenditure range of $5 billion to $5.5 billion and said it currently expects to complete most of its existing share-repurchase authorization, subject to market conditions and other factors.
On costs, Marks said same-facility cost per equivalent admission, including the effect of Medicaid supplemental payment programs, was essentially flat from a year earlier and improved 1.4% sequentially. He said HCA’s financial resiliency program—which includes digital transformation, global capabilities and expanded shared services—is intended to produce multiyear efficiency benefits. Professional fees remained elevated, rising about 8.5% year over year in the quarter, primarily due to anesthesia and radiology costs.
About HCA Healthcare (NYSE:HCA)HCA Healthcare is a for‑profit operator of healthcare facilities headquartered in Nashville, Tennessee. Founded in 1968, the company owns and operates a network of hospitals and related healthcare facilities and has grown through organic expansion and acquisitions to become a large provider of inpatient and outpatient services.
The company's core activities include the operation of acute care hospitals, freestanding surgical and emergency centers, and outpatient clinics. HCA's services encompass inpatient care, surgical services, emergency medicine, diagnostic imaging and laboratory testing, and various outpatient and ambulatory care offerings.
This instant news alert was generated by narrative science technology and financial data from MarketBeat in order to provide readers with the fastest reporting and unbiased coverage. Please send any questions or comments about this story to [email protected].
Should You Invest $1,000 in HCA Healthcare Right Now?Before you consider HCA Healthcare, you'll want to hear this.
MarketBeat keeps track of Wall Street's top-rated and best performing research analysts and the stocks they recommend to their clients on a daily basis. MarketBeat has identified the five stocks that top analysts are quietly whispering to their clients to buy now before the broader market catches on... and HCA Healthcare wasn't on the list.
While HCA Healthcare currently has a Moderate Buy rating among analysts, top-rated analysts believe these five stocks are better buys.
View The Five Stocks Here
Looking to profit from the electric vehicle mega-trend? Click the link to see our list of which EV stocks show the most long-term potential.
Key Takeaways HCA posted Q2 adjusted EPS of $7.59, beating estimates as revenues climbed 8.7% year over year.HCA saw higher admissions, revenue per admission and ER visits, while inpatient and outpatient surgeries fell.HCA narrowed revenue guidance but reduced adjusted EBITDA, net income and diluted EPS forecasts for 2026. HCA Healthcare, Inc. (HCA - Free Report) reported second-quarter 2026 adjusted earnings per share (EPS) of $7.59, which beat the Zacks Consensus Estimate of $7.57. The bottom line advanced 11% year over year.
Revenues rose 8.7% year over year to $20.2 billion. The top line was in line with the Zacks Consensus Estimate.
The quarterly results benefited from higher same-facility admissions, strong revenue per equivalent admission and solid emergency room visit growth. However, declining inpatient and outpatient surgeries, along with elevated operating expenses, partially offset these positives.
HCA Healthcare, Inc. Price, Consensus and EPS SurpriseHCA’s Q2 DetailsSame-facility equivalent admissions grew 2.7% year over year in the second quarter, beating our growth estimate of 2%. Meanwhile, same-facility admissions increased 2.5%, also surpassing our growth estimate of 1.8%.
Same-facility revenue per equivalent admission rose 6.4% year over year but came in higher than our growth estimate of 4.2%.
Same-facility inpatient surgeries fell 2.3% year over year, while same-facility outpatient surgeries dipped 3.4%. Same-facility emergency room visits inched up 3.6% year over year in the quarter.
Salaries and benefits, supplies and other operating expenses increased 9.8% year over year to $16.2 billion. The metric came in higher than our estimate of $15.4 billion.
Adjusted EBITDA of $4 billion advanced 4.6% year over year, which marginally beat our estimate of $3.9 billion.
HCA Healthcare operated 190 hospitals and roughly 2,600 ambulatory sites of care across 19 states and the United Kingdom as of June 30, 2026.
HCA’s Q2 Financial UpdateHCA Healthcare exited the second quarter with approximately $1 billion in cash and cash equivalents, down 2.6% from the 2025-end level. It had approximately $3.1 billion of available capacity under its credit facilities at the end of the reported quarter.
Total assets of $63.3 billion increased 4.2% from 2025-end figure.
Long-term debt, excluding debt issuance costs and discounts, was $43.5 billion, up 4.4% from the figure as of Dec. 31, 2025. Short-term borrowings and long-term debt due within a year totaled $6.3 billion.
Capital expenditures, excluding acquisitions, amounted to $1.2 billion during the quarter.
HCA’s Cash FlowCash flows from operating activities declined 44.5% year over year to $2.3 billion in the second quarter of 2026.
HCA Healthcare’s Capital Deployment UpdateHCA bought back shares worth approximately $2.1 billion in the second quarter. It had about $7.2 billion remaining under its share repurchase authorization as of June 30, 2026. The board also declared a quarterly cash dividend of 78 cents per share, payable on Sept. 30, 2026, to shareholders of record as of Sept. 16, 2026.
HCA Revises 2026 GuidanceRevenue guidance has been revised to $77.0-$79.5 billion from the previous $76.5-$80.0 billion, raising the lower end by $0.5 billion and lowering the upper end by $0.5 billion. The midpoint of the revised range implies 3.5% growth from the 2025 reported figure.
Adjusted EBITDA guidance has been narrowed to $15.4-$16.1 billion from $15.55-$16.45 billion. The midpoint suggests about 1.2% growth from the 2025 reported figure.
Net income guidance was lowered to $6.3-$6.7 billion from $6.495-$7.035 billion. The midpoint implies about a 4.2% decline from the 2025 reported figure.
Diluted EPS guidance was lowered to $28.70-$30.50 from $29.10-$31.50. The midpoint implies about 4.5% growth from the 2025 reported figure.
Capital expenditures, excluding acquisitions, remain projected in the range of $5.0-$5.5 billion.
HCA’s Zacks Rank & Key PicksHCA currently carries a Zacks Rank #4 (Sell).
Some better-ranked stocks in the broader Medical space are Charles River Laboratories International, Inc. (CRL - Free Report) , CVS Health Corporation (CVS - Free Report) and Cencora, Inc. (COR - Free Report) , each carrying a Zacks Rank #2 (Buy) at present. You can see the complete list of today’s Zacks #1 Rank (Strong Buy) stocks here.
Charles River is set to report second-quarter 2026 results on Aug. 5, before the market closes. The Zacks Consensus Estimate for earnings is pegged at $2.72 per share, which has witnessed one upward revision and one downward revision over the past 30 days. The company beat on earnings in each of the trailing four quarters, with the average surprise being 9.3%. The consensus estimate for Charles River’s second-quarter revenues is pinned at $970.77 million.
CVS Health is set to report second-quarter 2026 results on Aug. 5, before the market closes. The Zacks Consensus Estimate for earnings is pegged at $1.87 per share, indicating a 3.3% year-over-year increase. The company beat on earnings in each of the trailing four quarters, with the average surprise being 16.8%. The consensus estimate for CVS Health’s second-quarter revenues is pinned at $100.18 billion, indicating a 1.3% year-over-year increase.
Cencora is set to report second-quarter 2026 results on Aug. 5, before the market closes. The Zacks Consensus Estimate for earnings is pegged at $4.37 per share, indicating a 9.3% year-over-year increase. The company beat on earnings in three of the trailing four quarters and missed once, with the average surprise being 1.6%. The consensus estimate for Cencora’s second-quarter revenues is pinned at $84.89 billion, indicating a 5.2% year-over-year increase.
Getting big returns from financial portfolios, whether through stocks, bonds, ETFs, other securities, or a combination of all, is an investor's dream. But for income investors, generating consistent cash flow from each of your liquid investments is your primary focus.
While cash flow can come from bond interest or interest from other types of investments, income investors hone in on dividends. A dividend is that coveted distribution of a company's earnings paid out to shareholders, and investors often view it by its dividend yield, a metric that measures the dividend as a percent of the current stock price. Many academic studies show that dividends make up large portions of long-term returns, and in many cases, dividend contributions surpass one-third of total returns.
Based in Houston, CenterPoint Energy (CNP - Free Report) is in the Utilities sector, and so far this year, shares have seen a price change of 15.36%. Currently paying a dividend of $0.23 per share, the company has a dividend yield of 2.08%. In comparison, the Utility - Electric Power industry's yield is 3.1%, while the S&P 500's yield is 1.33%.
Looking at dividend growth, the company's current annualized dividend of $0.92 is up 4.5% from last year. Over the last 5 years, CenterPoint Energy has increased its dividend 5 times on a year-over-year basis for an average annual increase of 8.33%. Looking ahead, future dividend growth will be dependent on earnings growth and payout ratio, which is the proportion of a company's annual earnings per share that it pays out as a dividend. CenterPoint's current payout ratio is 51%, meaning it paid out 51% of its trailing 12-month EPS as dividend.
CNP is expecting earnings to expand this fiscal year as well. The Zacks Consensus Estimate for 2026 is $1.91 per share, which represents a year-over-year growth rate of 8.52%.
From greatly improving stock investing profits and reducing overall portfolio risk to providing tax advantages, investors like dividends for a variety of different reasons. But, not every company offers a quarterly payout.
Big, established firms that have more secure profits are often seen as the best dividend options, but it's fairly uncommon to see high-growth businesses or tech start-ups offer their stockholders a dividend. Income investors have to be mindful of the fact that high-yielding stocks tend to struggle during periods of rising interest rates. With that in mind, CNP presents a compelling investment opportunity; it's not only an attractive dividend play, but the stock also boasts a strong Zacks Rank of #2 (Buy).
CenterPoint Energy (CNP - Free Report) appears an attractive pick, as it has been recently upgraded to a Zacks Rank #2 (Buy). An upward trend in earnings estimates -- one of the most powerful forces impacting stock prices -- has triggered this rating change.
The Zacks rating relies solely on a company's changing earnings picture. It tracks EPS estimates for the current and following years from the sell-side analysts covering the stock through a consensus measure -- the Zacks Consensus Estimate.
Individual investors often find it hard to make decisions based on rating upgrades by Wall Street analysts, since these are mostly driven by subjective factors that are hard to see and measure in real time. In these situations, the Zacks rating system comes in handy because of the power of a changing earnings picture in determining near-term stock price movements.
As such, the Zacks rating upgrade for CenterPoint is essentially a positive comment on its earnings outlook that could have a favorable impact on its stock price.
Most Powerful Force Impacting Stock PricesThe change in a company's future earnings potential, as reflected in earnings estimate revisions, and the near-term price movement of its stock are proven to be strongly correlated. That's partly because of the influence of institutional investors that use earnings and earnings estimates for calculating the fair value of a company's shares. An increase or decrease in earnings estimates in their valuation models simply results in higher or lower fair value for a stock, and institutional investors typically buy or sell it. Their transaction of large amounts of shares then leads to price movement for the stock.
For CenterPoint, rising earnings estimates and the consequent rating upgrade fundamentally mean an improvement in the company's underlying business. And investors' appreciation of this improving business trend should push the stock higher.
Harnessing the Power of Earnings Estimate RevisionsAs empirical research shows a strong correlation between trends in earnings estimate revisions and near-term stock movements, tracking such revisions for making an investment decision could be truly rewarding. Here is where the tried-and-tested Zacks Rank stock-rating system plays an important role, as it effectively harnesses the power of earnings estimate revisions.
The Zacks Rank stock-rating system, which uses four factors related to earnings estimates to classify stocks into five groups, ranging from Zacks Rank #1 (Strong Buy) to Zacks Rank #5 (Strong Sell), has an impressive externally-audited track record, with Zacks Rank #1 stocks generating an average annual return of +25% since 1988. You can see the complete list of today's Zacks #1 Rank (Strong Buy) stocks here >>>> .
Earnings Estimate Revisions for CenterPointFor the fiscal year ending December 2026, this energy delivery company is expected to earn $1.91 per share, which is unchanged compared with the year-ago reported number.
Analysts have been steadily raising their estimates for CenterPoint. Over the past three months, the Zacks Consensus Estimate for the company has increased 0.1%.
Bottom LineUnlike the overly optimistic Wall Street analysts whose rating systems tend to be weighted toward favorable recommendations, the Zacks rating system maintains an equal proportion of "buy" and "sell" ratings for its entire universe of more than 4,000 stocks at any point in time. Irrespective of market conditions, only the top 5% of the Zacks-covered stocks get a "Strong Buy" rating and the next 15% get a "Buy" rating. So, the placement of a stock in the top 20% of the Zacks-covered stocks indicates its superior earnings estimate revision feature, making it a solid candidate for producing market-beating returns in the near term.
You can learn more about the Zacks Rank here >>>
The upgrade of CenterPoint to a Zacks Rank #2 positions it in the top 20% of the Zacks-covered stocks in terms of estimate revisions, implying that the stock might move higher in the near term.
Key Takeaways Unum is expected to benefit from favorable persistency and stronger sales across its insurance businesses. UNM's key operating segments are likely to see growth from voluntary benefits, life and disability products. Unum is expected to face higher expenses, while continued share buybacks may support earnings. Unum Group (UNM - Free Report) is expected to register an improvement in its bottom line but a decline in the top line when it reports second-quarter 2026 results on July 28, after the closing bell.
The Zacks Consensus Estimate for UNM’s second-quarter revenues is pegged at $2.95 billion, indicating a 12.6% decline from the year-ago reported figure.
The consensus estimate for earnings is pegged at $2.14 per share. The Zacks Consensus Estimate for UNM’s second-quarter earnings has moved south by 0.4% in the past 30 days. The estimate suggests a year-over-year increase of 3.3%.
What the Zacks Model Unveils for UNMOur proven model does not conclusively predict an earnings beat for Unum Group this time around. This is because a stock needs to have the right combination of a positive Earnings ESP and a Zacks Rank #1 (Strong Buy), 2 (Buy), or 3 (Hold). This is not the case, as you can see below:
Earnings ESP: Unum Group has an Earnings ESP of -0.89%. This is because the Most Accurate Estimate of $2.13 is pegged lower than the Zacks Consensus Estimate of $2.14. You can uncover the best stocks to buy or sell before they are reported with our Earnings ESP Filter.
Zacks Rank: Unum Group currently carries a Zacks Rank #3.
Factors Likely to Shape Q2 Results of UNMFavorable persistency and better sales in the operating segments are likely to have favored premiums in the second quarter. Our estimate and the Zacks Consensus Estimate for premium income are both pegged at $2.6 billion.
Net investment income is likely to have increased due to higher invested assets and higher miscellaneous investment income. Our estimate for investment income is pegged at $297.3 million, suggesting a 47% decrease from the year-ago quarter. The Zacks Consensus Estimate is pegged at $269 million.
The performance of Unum U.S. and Colonial Life — two of the largest operating segments — is likely to have been driven by stable overall persistency in the voluntary benefits and dental and vision product lines, and higher prior period sales in the voluntary benefits product line, improved benefit experience across life, accident, sickness, and disability product lines, and in-force block growth.
Better performance in life and group disability is likely to aid Unum U.S. results.
Our estimate for Unum U.S. operating revenues is pegged at $2 billion, while the same for Colonial Life is pinned at $516.5 million.
Favorable results at group long-term disability, Group Life and Supplemental are likely to have favored Unum UK. This, combined with in-force block growth, sales and favorable overall persistency at Unum Poland, is likely to have benefited Unum International. Our estimate for Unum International’s operating revenues is pegged at $336.1 million.
Expenses are likely to have increased because of higher policy benefits, commissions, interest and debt expense, amortization of deferred acquisition costs and other expenses.
Continued share buybacks are likely to have contributed to the bottom line.
Stocks to ConsiderSome insurance stocks with the right combination of elements to deliver an earnings beat this time around are:
Aflac Incorporated (AFL - Free Report) has an Earnings ESP of +0.34% and a Zacks Rank #3 at present. The Zacks Consensus Estimate for second-quarter 2026 earnings is pegged at $1.77, indicating a year-over-year decrease of 0.5%. You can see the complete list of today’s Zacks #1 Rank stocks here.
AFL’s earnings beat estimates in two of the last four reported quarters and missed in the other two.
The Allstate Corporation (ALL - Free Report) has an Earnings ESP of +2.59% and a Zacks Rank #2 at present. The Zacks Consensus Estimate for second-quarter 2026 earnings is pegged at $5.61, indicating a year-over-year decrease of 5.5%.
ALL’s earnings beat estimates in each of the last four reported quarters.
Axis Capital Holdings Limited (AXS - Free Report) has an Earnings ESP of +3.82% and a Zacks Rank #3 at present. The Zacks Consensus Estimate for second-quarter 2026 earnings is pegged at $3.23, indicating a year-over-year decrease of 1.8%.
AXS’s earnings beat estimates in each of the last four reported quarters.
Key Takeaways IQVIA's Q2 revenues are expected to rise 6.7% y/y to $4.3 billion, with EPS at $3.02.Commercial solutions growth is expected from drug launches, AI demand and Data-as-a-Service adoption.AI-led workflow gains and backlog conversion are expected to support research and development solutions. IQVIA Holdings Inc. (IQV - Free Report) is set to release second-quarter 2026 results on July 28, before market open.
IQV has a decent earnings surprise history, having surpassed the Zacks Consensus Estimate in the trailing four quarters, with an average surprise of 1.6%.
IQVIA’s Q2 ExpectationsThe Zacks Consensus Estimate for revenues is pegged at $4.3 billion, implying 6.7% year-over-year growth. Growth in the top line is likely to have been stimulated by an efficient use of AI across its business lines.
Revenue gains in the commercial solutions segment are expected to have emanated extensively from rising drug launch activity. Surging demand for the company’s exclusive AI capabilities, tailored AI agents and AI-ready data foundations is anticipated to have added to the growth trajectory.
We expect the rapid adoption of Data-as-a-Service, resulting in multi-year client agreements and enterprise-wide platform adoptions, enhancing commercial intelligence and analytics, to have acted as a major catalyst to this segment’s growth.
For the research and development solutions segment, we expect IQVIA to have leveraged AI to optimize workflow, accelerate study execution and cut down errors, thus improving its revenues. Scheduled conversion of contracted backlogs into revenues over the upcoming months is likely to have contributed to the segment’s growth.
The consensus estimate for earnings per share is $3.02, implying 7.5% year-over-year growth. Enhancement in operational prowess springing from high-margin revenue growth across segments is anticipated to have benefited the bottom line.
What Our Model Says About IQVOur proven model does not conclusively predict an earnings beat for IQVIA this time around. The combination of a positive Earnings ESP and a Zacks Rank #1 (Strong Buy), 2 (Buy) or 3 (Hold) increases the odds of an earnings beat. But that is not the case here. You can uncover the best stocks before they are reported with our Earnings ESP Filter.
IQV has an Earnings ESP of -2.98% and a Zacks Rank of 3 at present. You can see the complete list of today’s Zacks #1 Rank stocks here.
Stocks to ConsiderHere are a few stocks from the broader Medical sector, which, according to our model, have the right combination of elements to beat on earnings this time around.
Alcon (ALC - Free Report) : The Zacks Consensus Estimate for the company’s second-quarter 2026 revenues is pegged at $2.8 billion, indicating 7.3% year-over-year growth. For earnings, the consensus mark is pinned at 77 cents per share, moving up 1.3% from the year-ago quarter’s reported figure. The company beat the consensus estimate in three of the past four quarters and missed once, with an average surprise of 3.7%.
ALC carries an Earnings ESP of +3.13% and a Zacks Rank of 3 at present. The company is scheduled to declare second-quarter 2026 results on Aug. 10.
Waters (WAT - Free Report) : The Zacks Consensus Estimate for the company’s second-quarter 2026 revenues is pinned at $1.6 billion, hinting at 3% year-over-year growth. For earnings, the consensus mark is pinned at $3.01 per share, improving 2% from the year-ago quarter’s reported figure. WAT beat the consensus estimate for earnings in the trailing four quarters, with an average surprise of 6%.
WAT has an Earnings ESP of +0.45% and a Zacks Rank of 3 at present. The company is scheduled to declare second-quarter 2026 results on Aug. 4.
Key Takeaways Liquidia's Yutrepia launch has driven strong sales, adoption and three straight profitable quarters. LQDA projects far faster 2026 revenue and EPS growth, backed by rising earnings estimates.United Therapeutics counters with a broad PAH portfolio and late-stage ralinepag pipeline. Liquidia Corporation (LQDA - Free Report) is a commercial-stage biopharmaceutical company focused on developing and commercializing therapies for pulmonary arterial hypertension (PAH) and pulmonary hypertension associated with interstitial lung disease (PH-ILD).
United Therapeutics (UTHR - Free Report) boasts six FDA-approved therapies that treat PAH, PH-ILD, and neuroblastoma, a rare pediatric cancer, in its portfolio.
Liquidia and United Therapeutics are locked in a fierce battle in the PAH market, with Liquidia's Yutrepia emerging as a challenger to United Therapeutics' blockbuster Tyvaso franchise. Their competition extends beyond commercial sales to patent disputes and a race to capture a larger share of the inhaled treprostinil market.
Given this backdrop, selecting one stock over the other can be difficult. We therefore evaluate their fundamentals, growth prospects, challenges and valuation metrics to help make an informed decision.
The Case for LQDALiquidia currently markets Yutrepia (treprostinil) inhalation powder, approved by the FDA in May 2025 and launched the following month commercially.
The company also generates revenues through a profit-sharing agreement with Sandoz for the promotion of its generic treprostinil injection in the United States.
Yutrepia is an inhaled dry-powder formulation of treprostinil developed using Liquidia's proprietary PRINT particle engineering technology. The platform is designed to enhance deep lung drug delivery, simplify administration through a low-effort dry-powder inhaler and enable higher dose levels than currently marketed inhaled treprostinil therapies.
The company supports commercialization through a specialized sales force focused on physicians treating PAH and PH-ILD, as well as stakeholders involved in reimbursement and drug distribution.
Since its launch in June 2025, Yutrepia has emerged as a strong growth driver, generating approximately $130 million in first-quarter 2026 sales. The therapy has demonstrated robust adoption, with more than 4,500 unique prescriptions, around 3,750 patients initiating treatment, and nearly 1,000 physicians prescribing the drug.
Its rapid uptake helped Liquidia post its third consecutive profitable quarter, highlighting Yutrepia's growing commercial success.
Beyond its commercial portfolio, Liquidia is advancing a pipeline of therapies for pulmonary vascular diseases. Its lead pipeline candidate, L606, is an investigational liposomal formulation of treprostinil administered twice daily via a next-generation nebulizer. L606 is being evaluated in an open-label study for PAH and PH-ILD, while a global pivotal placebo-controlled trial is underway in PH-ILD.
Liquidia also plans to expand Yutrepia into additional indications, including pulmonary hypertension associated with chronic obstructive pulmonary disease (PH-COPD), idiopathic pulmonary fibrosis (IPF), progressive pulmonary fibrosis (PPF) and Raynaud's phenomenon associated with systemic sclerosis.
The Case for UTHRUnited Therapeutics markets a broad PAH portfolio led by Tyvaso DPI, a dry-powder inhaled formulation of the prostacyclin analogue treprostinil, which was approved by FDA in May 2022 to improve exercise ability in patients with PAH and PH-ILD.
Its portfolio includes nebulized Tyvaso, a nebulized liquid inhaled formulation of treprostinil, approved by the FDA to improve exercise ability in patients with PAH and PH-ILD.
The company also markets Remodulin, a continuously infused treprostinil therapy for PAH administered subcutaneously or intravenously, supported by the user-friendly RemunityPRO infusion pump. Its PAH portfolio further includes Orenitram, an oral extended-release treprostinil tablet, and Adcirca (tadalafil), an oral PDE-5 inhibitor licensed from Eli Lilly through the end of 2026.
Sales of Tyvaso products continue to grow, driven by higher volumes and continued growth in commercialization utilization. Moreover, Orenitram offers a convenient oral treatment option that avoids the challenges associated with continuous infusion therapies, such as Remodulin, and inhaled therapies requiring multiple daily administrations.
The company remains focused on developing additional therapies for PAH and pulmonary fibrosis (PF).
Ralinepag, an investigational, highly selective and potent prostacyclin (IP) receptor, is one of United Therapeutics' most promising late-stage pipeline assets. The candidate is being developed in two formulations — an oral version and a DPI version (RAL-DPI).
Based on positive data from the pivotal phase III ADVANCE OUTCOMES study, United Therapeutics intends to submit a new drug application for ralinepag (to treat PAH) to the FDA by the second half of 2026.
If approved, oral ralinepag could strengthen United Therapeutics’ leadership in PAH and potentially offset future competitive pressure on older products.
Beyond the oral formulation, United Therapeutics is also developing inhaled dry-powder versions of ralinepag, RAL-DPI, in collaboration with MannKind Corporation. While initially targeting PAH, management sees opportunities for RAL-DPI in PH-ILD, IPF and PPF. Together, the oral and inhaled formulations position ralinepag as a potential cornerstone of United Therapeutics' future growth strategy.
Outside its PAH franchise, the company markets Unituxin for the treatment of high-risk neuroblastoma.
UTHR strengthened its long-term regenerative medicine strategy by acquiring preclinical stage biotech Thymmune Therapeutics for $140 million upfront, with up to $160 million in milestone payments. The deal adds THY-100, a stem cell-derived thymic cell therapy being developed for congenital athymia, and a platform with potential applications in organ transplantation, autoimmune diseases and immune deficiencies. The acquisition broadens United Therapeutics' pipeline beyond PAH.
A Look at Estimates: LQDA versus UTHRThe Zacks Consensus Estimate for LQDA’s 2026 sales implies a year-over-year increase of 315.77%, while that for earnings per share (EPS) suggests a year-over-year improvement of 477.5%. The Zacks Consensus Estimate for 2026 EPS has moved north to $3.02 from $2.97 and that for 2027 EPS has increased to $4.92 from $4.81 in the past 60 days.
LQDA’s Estimate Movement
Image Source: Zacks Investment Research
The Zacks Consensus Estimate for UTHR’s 2026 sales implies a year-over-year increase of 1.46%, while that for EPS suggests a year-over-year decline of 4.41%. EPS estimates for 2026 have moved south to $26.63 in the past 60 days but those for 2026 have moved north to $31.66 from $31.09 during the said time frame.
UTHR’s Estimate Movement
Image Source: Zacks Investment Research
Price Performance and Valuation of LQDA and UTHRFrom a price-performance perspective, LQDA has fetched better returns than UTHR so far in the year. Shares of LQDA have surged 158.2%, while those of UTHR have gained 8.7%. The industry has gained 1.4% in the said period.
Image Source: Zacks Investment Research
From a valuation standpoint, LQDA is more expensive than UTHR. LQDA’s shares currently trade at 8.74X forward sales, higher than 6.50X for UTHR.
Image Source: Zacks Investment Research
Which Stock Is a Better Pick for Now?LQDA currently sports a Zacks Rank #1 (Strong Buy), while UTHR carries a Zacks Rank #2 (Buy). You can see the complete list of today’s Zacks #1 Rank stocks here.
Although United Therapeutics remains the established leader in PAH with a diversified portfolio, a robust late-stage pipeline and expansion into regenerative medicine, much of its growth appears incremental.
In contrast, Liquidia is in the early stages of a rapid commercial expansion, driven by the impressive launch of Yutrepia, expanding label opportunities and a promising pipeline. The company's superior revenue and earnings growth outlook, upward estimate revisions, stronger year-to-date share price performance and better Zacks Rank outweigh its premium valuation.
While UTHR remains a solid long-term holding, Liquidia offers the more compelling growth story and greater upside potential at current levels, making LQDA the better pick for investors seeking higher returns.
Signature Youth Initiative Anchors the Second Annual Impacting the Carolinas Campaign; First Horizon Bank Named Presenting Partner of Bee-Ball For All
, /PRNewswire/ -- The Charlotte Hornets have announced First Horizon Bank (NYSE: FHN or "First Horizon") as the presenting partner of Bee-Ball for All, the organization's signature youth engagement platform and cornerstone of the second annual Impacting the Carolinas initiative. Through Bee-Ball for All presented by First Horizon Bank, the Hornets will distribute 10,000 basketballs to youth through participating Boys & Girls Club locations across North and South Carolina, expanding access to the game while creating opportunities for mentorship, literacy, wellness and community engagement throughout the region.
First Horizon Bank and Charlotte Hornets Bee-Ball for All Event - Northridge Middle School, Charlotte NC To officially tip off the initiative, Hornets, First Horizon Bank and Boys & Girls Club leaders – along with Hornets Legend Muggsy Bogues – gathered at Northridge Middle School on Thursday, July 23 for a formal announcement and youth basketball clinic celebrating the launch of the two-state distribution effort. The event served as the beginning of a broader effort that will place 10,000 basketballs into the hands of children across North and South Carolina.
"This isn't just about giving away basketballs; it's about opening doors for youth development in multiple ways," said Justin Rutledge, Senior Vice President and Charlotte Market President for First Horizon Bank. Laura Bunn, Executive Vice President and Mid-Atlantic Regional President for First Horizon Bank added, "Sports also build teamwork, discipline and skills youth will carry through their lives. While we're proud to celebrate in Charlotte today, the mission reaches far beyond this community. Bee-Ball for All helps us connect with youth across the Carolinas, so opportunities aren't limited to one city, but shared across more than 200 Boys & Girls Clubs spanning North and South Carolina."
"Partnerships like this allow us to make a greater impact than we ever could alone. We are incredibly grateful to First Horizon Bank for sharing our commitment to investing in youth and strengthening communities throughout the Carolinas," said Hornets Sports & Entertainment Senior Vice President of Community Impact Betsy Mack. "Together, we are creating opportunities for young people to grow, learn, build confidence and connect through the game of basketball."
Launched in 2025, Impacting the Carolinas is designed to strengthen Hornets Sports & Entertainment's community impact and regional presence across North and South Carolina while reinforcing the organization's commitment to being the Team of the Carolinas.
About First Horizon
First Horizon Corp. (NYSE: FHN), with $84.4 billion in assets as of June 30, 2026, is a leading regional financial services company, dedicated to helping our clients, communities and associates unlock their full potential with capital and counsel. Headquartered in Memphis, TN, the banking subsidiary First Horizon Bank operates in 12 states concentrated in the southern U.S. The Company and its subsidiaries offer commercial, private banking, consumer, small business, wealth and trust management, retail brokerage, capital markets, fixed income, and mortgage banking services. First Horizon has been recognized as one of the nation's best employers by Fortune and Forbes magazines and a Top 10 Most Reputable U.S. Bank. More information is available at www.FirstHorizon.com.
About Hornets Sports & Entertainment
Hornets Sports & Entertainment (HSE) owns the Charlotte Hornets and the Greensboro Swarm (NBA G League), and operates Spectrum Center, the premier destination for sports and entertainment in the Carolinas. Charlotte's first professional sports team, the Hornets joined the NBA in 1988 and are a member of the Eastern Conference's Southeast Division. HSE is committed to positively impacting the Carolinas through community programming and the Charlotte Hornets Foundation. Spectrum Center is celebrating its 20th anniversary and reopened following a two-phased renovation as a fully transformed world-class arena in the heart of Uptown Charlotte. Through the years, Spectrum Center has hosted nearly 2,500 events and has welcomed more than 25 million guests. Directly across from Spectrum Center, the state-of-the-art Novant Health Performance Center is being built to enhance player development and foster a culture of high performance.
For more information, please visit hornets.com, gsoswarm.com or spectrumcentercharlotte.com
Two hot tech stocks and a quieter healthcare mover take the attention of @Stockstotrade's Tim Bohen to close out the trading week. He sees Alphabet (GOOGL) tapping notable support as a tentative buy opportunity, expects Super Micro (SMCI) to make a similar bull run it saw earlier this week, and points to CVS Health (CVS) as a reliable, low beta stock.
First Hawaiian NASDAQ: FHB executives said the bank delivered loan growth, wider net interest margin and continued solid credit quality in the second quarter of 2026, while preparing for its proposed combination with TriCo Bancshares.
Chairman, President and CEO Bob Harrison said the company was “very excited” about the TriCo transaction, which is expected to close near the end of the year. He said First Hawaiian is focused on the work required to complete the deal and does not have additional information beyond what was presented during its July 23 investor call.
Get First Hawaiian alerts:
Hawaii economy and loan growth Harrison pointed to relatively stable economic conditions in Hawaii. The statewide employment rate was 2.5% in May, compared with a national unemployment rate of 4.3%. Total visitor arrivals through May rose 2.9% from a year earlier, driven primarily by visitors from the U.S. mainland and Japan, while year-to-date visitor spending reached $9.7 billion, up 7.5% from 2025 levels.
Hawaii housing prices also remained firm. The median Oahu single-family home sales price was $1.2 million in June, up 10.4% year over year, while the median condo price was $528,000, up 3.5%.
Total loans increased $137 million during the quarter, representing annualized growth of about 3.6%. Growth was led by commercial and industrial, or C&I, lending and commercial real estate lending. C&I balances increased $98 million, primarily because of dealer-flooring growth and expansion in the company’s Hawaii corporate portfolio.
Completed construction projects resulted in the conversion of $95 million in construction loan balances into commercial real estate loans. Construction loan payoffs and lower residential balances partly offset the broader growth, as residential payoffs exceeded new production.
Harrison said management continues to see a “very robust pipeline” in C&I and commercial real estate, with construction activity representing a meaningful portion of commercial real estate opportunities. The bank also is working with some new customer relationships, he said. Residential lending, however, is expected to remain slow because of the interest-rate environment.
Deposits, margin and earnings outlook Total deposits declined $623 million in the second quarter, largely due to expected public-deposit outflows. Chief Financial Officer Jamie Moses said retail deposits were essentially flat, while commercial deposits fell about $156 million because of seasonal volatility. Public deposits declined $467 million, mainly in operating accounts, and public time deposits decreased by $115 million. The remaining public time-deposit balance was $9 million.
Moses said the declines did not reflect lost customer relationships. Municipal partners found other ways to invest certain balances off the bank’s balance sheet, he said, while First Hawaiian expects retail and commercial deposits to increase in the second half because of seasonal patterns. The company’s noninterest-bearing deposit ratio was 32%, and its total cost of deposits declined two basis points from the first quarter.
Net interest income increased $3.5 million sequentially to $171 million. Net interest margin rose six basis points to 3.25%, helped by deposit mix and repricing, higher loan and securities yields, and lower cash balances.
Management revised its full-year net interest margin outlook to a range of 3.24% to 3.25%, based on market expectations for one rate increase later this year. First Hawaiian expects third-quarter margin of about 3.27%. Moses said the company assumed a rate increase early in the fourth quarter in its outlook.
The balance sheet remains asset-sensitive, according to Harrison. Moses said roughly $6 billion of assets would reprice immediately following a rate increase based on SOFR, while approximately $3.5 billion to $4 billion of liabilities would also reprice to some degree.
Cash balances declined in the quarter primarily because of public-deposit outflows. Management expects to keep cash around the quarter-end level, approximately $1 billion, through the rest of the year, even as it anticipates further loan growth.
Fees, expenses and credit quality Noninterest income totaled $60.3 million, aided by higher bank-owned life insurance income, an excise tax refund and increased swap fees. Moses said the BOLI contribution reflected a component of the portfolio that is sensitive to market movements rather than a death benefit.
First Hawaiian maintained its full-year noninterest income outlook of about $220 million. Moses said the company generally views approximately $55 million per quarter as a baseline, though one-time or market-related items can cause quarterly variation.
Noninterest expense was $130.4 million, including $4.2 million in costs related to the TriCo transaction. The company expects more transaction costs in the second half as it moves toward closing and integration. Excluding TriCo-related costs, First Hawaiian expects reported expenses of $515 million to $520 million for the full year.
Moses said higher second-half expenses will reflect continued hiring to support loan growth, along with project-related salary, professional-services and information-technology costs.
Chief Risk Officer Lea Nakamura said credit performance and credit metrics remained healthy. The allowance for credit losses declined both in dollar terms and relative to coverage, primarily because of a material reduction in classified assets.
The company reported a return on average tangible assets of 1.28% and a return on average tangible equity of 16.34% for the quarter. Its effective tax rate was 22.9%.
TriCo transaction and capital plans Harrison said First Hawaiian did not repurchase shares during the second quarter and is unlikely to conduct buybacks for the remainder of the year while the TriCo deal proceeds through regulatory review, though he said that could change. The company’s common equity tier 1 ratio remained above 13%, according to an analyst’s question during the call.
Management reiterated a target of 25% cost savings from the TriCo transaction. Moses said the company remains comfortable with that objective and expects to achieve it through a variety of measures, but did not provide further detail.
Harrison said three TriCo executives—Richard Smith, Dan Bailey and Peter G. Wiese—are expected to join First Hawaiian’s senior management team. He said First Hawaiian intends to retain much of TriCo’s management team, describing the California bank as a well-run institution that First Hawaiian plans to support while learning from its operations.
About First Hawaiian (NASDAQ:FHB)First Hawaiian, Inc is the oldest and largest bank in Hawaii, operating as the bank holding company for First Hawaiian Bank. Established in 1858, the company offers a full suite of financial services to individual, business and institutional clients. Its product portfolio includes consumer and commercial lending, deposit accounts, treasury and cash management, foreign exchange and trade finance, as well as wealth management and trust services.
First Hawaiian serves customers through an extensive network of branches, ATMs and digital channels across the Hawaiian Islands, Guam, Saipan and American Samoa.
This instant news alert was generated by narrative science technology and financial data from MarketBeat in order to provide readers with the fastest reporting and unbiased coverage. Please send any questions or comments about this story to [email protected].
Should You Invest $1,000 in First Hawaiian Right Now?Before you consider First Hawaiian, you'll want to hear this.
MarketBeat keeps track of Wall Street's top-rated and best performing research analysts and the stocks they recommend to their clients on a daily basis. MarketBeat has identified the five stocks that top analysts are quietly whispering to their clients to buy now before the broader market catches on... and First Hawaiian wasn't on the list.
While First Hawaiian currently has a Hold rating among analysts, top-rated analysts believe these five stocks are better buys.
View The Five Stocks Here
MarketBeat just released its list of the 7 hottest IPOs expected to hit Wall Street in 2026. See which companies are preparing to go public and why investors are watching closely.
SouthState Bank NYSE: SSB reported second-quarter 2026 results marked by continued loan growth, stable net interest margin, low credit losses and ongoing investment in banker recruiting and artificial intelligence initiatives.
Chief Executive Officer John Corbett said the company generated a 1.36% return on assets and a 17.6% return on tangible common equity during the quarter. He said results reflected “solid balance sheet growth, stable margins, improving efficiency, and continued strength in credit quality.”
Over the past year, loans increased 8% and deposits rose 5%, both within the company’s previously issued guidance ranges. During the second quarter, loan growth totaled $1.35 billion, representing an 11% annualized rate. Average loan growth also ran at an 11% annualized pace.
Get SouthState Bank alerts:
Corbett said growth was broad-based across SouthState’s footprint, with Florida leading the company in loan-growth dollars. Florida, Texas and South Carolina were the largest contributors by dollar amount, while Atlanta, Virginia and Alabama posted strong percentage growth, including commercial and industrial lending gains in Atlanta.
Recruiting Supports Growth Strategy SouthState has expanded its commercial banking sales force by more than 10% over the past three quarters as it seeks to capitalize on disruption in its markets. Corbett said the company had offered division presidents the opportunity to increase their commercial relationship manager teams by 15% to 20% over several years.
The newer hires have generated $600 million of loan production so far and have a $1.5 billion pipeline, according to Corbett. Texas has been the strongest market for sales-force expansion, with its commercial relationship manager count up 25%.
The company expects loan growth to remain in the mid- to upper-single-digit range. Corbett said SouthState sees a potential mix shift in the second half, with commercial and industrial lending expected to increase while planned commercial real estate payoffs, including multifamily projects, rise.
Construction lending increased during the quarter, driven partly by owner-occupied projects for commercial clients and multifamily construction. However, Corbett noted that the overall construction category remained about 10% below its level a year earlier.
Margin Outlook Remains Stable SouthState reported a net interest margin of 3.78%, down 1 basis point from the first quarter and within its 3.75% to 3.80% guidance range. Deposit costs were unchanged from the prior quarter at 1.76%, while loan yields declined 5 basis points to 5.91% due to lower purchase-accounting accretion income.
Excluding accretion, loan yields increased 1 basis point and net interest margin rose 4 basis points, the company said. Net interest income totaled $576 million, up $14 million from the first quarter.
Chief Strategy Officer Steve Young said management’s outlook assumes no interest-rate increases or reductions through 2027 and calls for net interest margin to remain within the 3.75% to 3.80% range. He said deposit costs could rise modestly as the company funds loan growth, but anticipated asset repricing should help support the margin.
SouthState said approximately 76% of quarterly loan production carried floating rates. The share of the overall loan portfolio in floating-rate loans has increased to 38%, from 32% a year earlier.
Management also pointed to future repricing opportunities, including roughly $6 billion of loans expected to reprice over the next year and about $1 billion of securities expected to cash flow and be reinvested. Young said legacy loans with coupons in the 3% to 4% range are being replaced at rates in the 6% range.
Credit Quality and Expenses Credit quality improved during the quarter. Nonperforming assets declined 14%, classified loans also decreased, and net charge-offs were 6 basis points. It was the eighth time in the past nine quarters that SouthState’s net charge-offs were below 10 basis points.
Provision expense was $16 million, primarily reflecting loan growth. Management said it expects modest downward pressure on reserve levels absent meaningful changes in Moody’s economic forecasts and other loss drivers. The company continues to use a more conservative weighting toward Moody’s pessimistic scenario than its traditional model weighting.
Noninterest income was $97 million, or 57 basis points of average assets, within the company’s 55- to 60-basis-point guidance range. The figure was $3 million below the first quarter, as higher deposit fees were offset by lower mortgage revenue. SouthState said it continues to expect correspondent banking revenue of roughly $25 million per quarter.
Noninterest expense totaled $358 million, slightly better than guidance. Management maintained its forecast for 4% noninterest expense growth in 2026. It expects compensation costs to rise in the second half as recently hired employees remain in the run rate and company merit increases take effect July 1.
Capital Returns and Technology Investment SouthState repurchased 1 million shares during the quarter at a weighted average price of $97.62, producing a 68% total payout ratio including dividends. Year-to-date repurchases totaled 2.5 million shares and the total payout ratio was 80%.
Corbett said the company repurchased nearly 5% of its outstanding shares over the past year while increasing its dividend and maintaining a common equity tier 1 capital ratio above 11%. CET1 ended the quarter at 11.1%, tangible common equity was 8.7%, and tangible book value per share was $58.72, up 13% from a year earlier.
Management reiterated its longer-term total capital return framework of 40% to 60%, saying recent higher repurchase activity is not expected to be sustained if the company continues to target mid- to high-single-digit loan growth while maintaining CET1 in an 11% to 12% range.
Corbett also highlighted artificial intelligence as a strategic priority. The company is using the technology in credit operations, fraud management and call-center support, as well as through an internally developed small language model. SouthState is also testing commodity-hedging and foreign-exchange offerings, though Young said those initiatives are expected to launch in 2027 rather than materially affect 2026 results.
About SouthState Bank (NYSE:SSB)SouthState Bank NYSE: SSB is a bank holding company headquartered in Winter Haven, Florida, that provides a range of commercial and retail banking services. Through its subsidiary, SouthState Bank, the company serves businesses, institutions and individuals with deposit, lending and treasury management solutions. Its core business lines include commercial and industrial loans, commercial real estate lending, consumer mortgages and home equity loans.
In addition to traditional lending and deposit products, SouthState Bank offers specialized services such as treasury and cash management, merchant services, payment solutions and online banking.
This instant news alert was generated by narrative science technology and financial data from MarketBeat in order to provide readers with the fastest reporting and unbiased coverage. Please send any questions or comments about this story to [email protected].
Should You Invest $1,000 in SouthState Bank Right Now?Before you consider SouthState Bank, you'll want to hear this.
MarketBeat keeps track of Wall Street's top-rated and best performing research analysts and the stocks they recommend to their clients on a daily basis. MarketBeat has identified the five stocks that top analysts are quietly whispering to their clients to buy now before the broader market catches on... and SouthState Bank wasn't on the list.
While SouthState Bank currently has a Moderate Buy rating among analysts, top-rated analysts believe these five stocks are better buys.
View The Five Stocks Here
Enter your email address and we’ll send you MarketBeat’s list of ten stocks set to soar in Summer 2026, despite the threat of tariffs and what's happening in Iran. These ten stocks are incredibly resilient and are likely to thrive in any economic environment.
SouthState Bank Corporation (SSB) Q2 2026 Earnings Call July 24, 2026 9:00 AM EDT
Company Participants
William Matthews - Senior Executive VP & CFO
John Corbett - CEO & Chairman
Stephen Young - Senior Executive VP & Chief Strategy Officer
Conference Call Participants
Stephen Scouten - Piper Sandler & Co., Research Division
John McDonald - Truist Securities, Inc., Research Division
Hannah Wynn - Keefe, Bruyette, & Woods, Inc., Research Division
Michael Rose - Raymond James & Associates, Inc., Research Division
Sun Young Lee - TD Cowen, Research Division
Gary Tenner - D.A. Davidson & Co., Research Division
Anthony Elian - JPMorgan Chase & Co, Research Division
Benjamin Gerlinger - Citigroup Inc., Research Division
David Chiaverini - Jefferies LLC, Research Division
David Bishop - Hovde Group, LLC, Research Division
Samuel Varga - UBS Investment Bank, Research Division
Presentation
Operator
Hello, everyone. Thank you for joining us, and welcome to the SouthState Bank Corporation Second Quarter 2026 Earnings Conference Call. [Operator Instructions]
I will now hand the conference call over to Will Matthews, Chief Financial Officer. Mr. Matthews, please go ahead.
William Matthews
Senior Executive VP & CFO
Good morning. This is Will Matthews, and welcome to SouthState's Second Quarter 2026 Earnings Call.
I'm here with John Corbett, Steve Young and Jeremy Lucas. We'll follow our typical pattern of brief prepared remarks and then move into Q&A. And I'll refer you to the Investor Relations tab of our website for the earnings materials.
Before we begin our remarks, I want to remind you that comments we make may include forward-looking statements within the meaning of the federal securities laws and regulations. Any such forward-looking statements we may make are subject to the safe harbor rules. Please review the forward-looking disclaimer and safe harbor language in the press release and presentation for more information about our forward-looking statements and risks and uncertainties, which may affect us.